<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">104894</article-id><article-id pub-id-type="doi">10.7554/eLife.104894</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.104894.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>TRPV4 activation by TGFβ2 enhances cellular contractility and drives ocular hypertension</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rudzitis</surname><given-names>Christopher Nass</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lakk</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Ayushi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Redmon</surname><given-names>Sarah N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kirdajová</surname><given-names>Denisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tseng</surname><given-names>Yun-Ting</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>De Ieso</surname><given-names>Michael L</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Stamer</surname><given-names>W Daniel</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Herberg</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Krizaj</surname><given-names>David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4468-3029</contrib-id><email>david.krizaj@hsc.utah.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Ophthalmology and Visual Sciences</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Department of Neurobiology, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Ophthalmology and Visual Sciences</institution><addr-line><named-content content-type="city">Syracuse</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040kfrw16</institution-id><institution>Department of Cell and Developmental Biology, SUNY Upstate Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Syracuse</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Ophthalmology, Duke Eye Center, Duke University</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040kfrw16</institution-id><institution>Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Syracuse</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Department of Bioengineering, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Poole</surname><given-names>Kate</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>UNSW Sydney</institution></institution-wrap><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Maduke</surname><given-names>Merritt</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>06</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP104894</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-11-06"><day>06</day><month>11</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-11-08"><day>08</day><month>11</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.11.05.622187"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-01-21"><day>21</day><month>01</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104894.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-11"><day>11</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104894.2"/></event></pub-history><permissions><copyright-statement>© 2025, Rudzitis et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Rudzitis et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-104894-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-104894-figures-v1.pdf"/><abstract><p>The risk for developing primary open-angle glaucoma (POAG) correlates with the magnitude of ocular hypertension (OHT) and the concentration of transforming growth factor-β2 (TGFβ2) in the aqueous humor. Effective treatment of POAG requires a detailed understanding of the interaction between pressure sensing mechanisms in the trabecular meshwork (TM) and biochemical risk factors. Here, we employed molecular, optical, electrophysiological, and tonometric strategies to establish the role of TGFβ2 in transcription and functional expression of mechanosensitive channel isoforms alongside studies of TM contractility in biomimetic hydrogels and intraocular pressure (IOP) regulation in a mouse model of TGFβ2-induced OHT. TGFβ2 upregulated expression of <italic>Trpv4</italic> and <italic>Piezo1</italic> transcripts and time-dependently augmented functional TRPV4 activation. TRPV4 agonists induced contractility of TM-seeded hydrogels, whereas pharmacological inhibition suppressed TGFβ2-induced hypercontractility and abrogated OHT in eyes overexpressing TGFβ2. <italic>Trpv4</italic>-deficient mice resisted TGFβ2-driven increases in IOP, but nocturnal OHT was not additive to TGFβ-evoked OHT. Our study establishes the fundamental role of TGFβ as a modulator of mechanosensing in nonexcitable cells, identifies the TRPV4 channel as the final common mechanism for TM contractility and circadian and pathological OHT, and offers insights for future treatments that can lower IOP in the sizeable cohort of hypertensive glaucoma patients that resist current treatments.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>TRPV4</kwd><kwd>glaucoma</kwd><kwd>intraocular pressure</kwd><kwd>TGFB2</kwd><kwd>contractility</kwd><kwd>circadian rhythm</kwd><kwd>calcium</kwd><kwd>electrophysiology</kwd><kwd>knockout mice</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Human (cells)</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>T32EY024234</award-id><principal-award-recipient><name><surname>Rudzitis</surname><given-names>Christopher Nass</given-names></name><name><surname>Krizaj</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01EY022076</award-id><principal-award-recipient><name><surname>Krizaj</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R0EY1031817</award-id><principal-award-recipient><name><surname>Krizaj</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>P30EY014800</award-id><principal-award-recipient><name><surname>Krizaj</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01EY034096</award-id><principal-award-recipient><name><surname>Herberg</surname><given-names>Samuel</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01EY022359</award-id><principal-award-recipient><name><surname>Stamer</surname><given-names>W Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01EY005722</award-id><principal-award-recipient><name><surname>Stamer</surname><given-names>W Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Crandall Glaucoma Initiative</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Krizaj</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Stauss-Ranking Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Krizaj</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001818</institution-id><institution>Research to Prevent Blindness</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Stamer</surname><given-names>W Daniel</given-names></name><name><surname>Krizaj</surname><given-names>David</given-names></name><name><surname>Herberg</surname><given-names>Samuel</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21EY036189</award-id><principal-award-recipient><name><surname>Herberg</surname><given-names>Samuel</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The TRPV4 channel was identified as an obligatory regulator of physiological and pathological increases in intraocular pressure.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Primary open-angle glaucoma (POAG), an irreversible blinding disease, afflicts ~3.5% of the global population (<xref ref-type="bibr" rid="bib96">Tham et al., 2014</xref>). Its incidence and severity are proportional to the amplitude and duration of ocular hypertension (OHT) (<xref ref-type="bibr" rid="bib29">Gordon et al., 2002</xref>; <xref ref-type="bibr" rid="bib34">Heijl et al., 2002</xref>), which correlates with retinal ganglion cell dysfunction, neuroinflammation, and oxidative stress (<xref ref-type="bibr" rid="bib6">Almasieh et al., 2012</xref>; <xref ref-type="bibr" rid="bib8">Baudouin et al., 2021</xref>). Biomechanical factors, glucocorticoids, and the cytokine transforming growth factor-β2 (TGFβ2) contribute to POAG by compromising the funneling of aqueous humor (AH) from the trabecular meshwork (TM) into Schlemm’s canal (SC). Elevated intraocular pressure (IOP) enhances the contractility of the juxtacanalicular TMi, a circumocular tissue comprised of extracellular matrix (ECM) beams populated by mechanosensitive and smooth muscle-like cells—thereby increasing AH outflow resistance. The molecular mechanism that links TM pressure sensing to the contractile response is not known but is likely to underpin the tissue’s sensitivity to compressive, tensile, osmotic, shear, and traction forces which collectively regulate expression of numerous TM genes and secretion of ECM proteins (<xref ref-type="bibr" rid="bib10">Borrás, 2003</xref>; <xref ref-type="bibr" rid="bib70">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">de Kater et al., 1992</xref>; <xref ref-type="bibr" rid="bib48">Krizaj, 2020</xref>; <xref ref-type="bibr" rid="bib9">Baumann et al., 2024</xref>; <xref ref-type="bibr" rid="bib13">Brubaker, 1975</xref>; <xref ref-type="bibr" rid="bib44">Karimi et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Patel et al., 2020</xref>).</p><p>The increase in trabecular outflow resistance induced by mechanical stress, glucocorticoids, and TGFβ2 manifests through two distinct components: a dynamic, reversible phase amenable to cytoskeletal and Rho kinase inhibition, and a chronic phase, characterized by transdifferentiation of TM cells into fibrotic and contractile myofibroblasts (<xref ref-type="bibr" rid="bib2">Acott et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Fuchshofer and Tamm, 2012</xref>; <xref ref-type="bibr" rid="bib41">Johnstone, 2014</xref>). TGFβ2-induced fibrotic remodeling has been linked to POAG: (1) TM cells derived from POAG patients secrete more active TGFβ2 compared to cells isolated from healthy donors (<xref ref-type="bibr" rid="bib55">Li et al., 2022b</xref>), (2) the risk of POAG is proportional to [TGFβ2]<sub>AH</sub> (<xref ref-type="bibr" rid="bib4">Agarwal et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Ochiai and Ochiai, 2002</xref>; <xref ref-type="bibr" rid="bib99">Tripathi et al., 1994</xref>), and (3) ectopic ocular expression of TGFβ2 suffices to induce OHT (<xref ref-type="bibr" rid="bib71">Patil et al., 2022</xref>; <xref ref-type="bibr" rid="bib91">Shepard et al., 2010</xref>), likely via aberrant secretion of ECM proteins and enhanced TM contractility (<xref ref-type="bibr" rid="bib25">Fleenor et al., 2006</xref>; <xref ref-type="bibr" rid="bib62">Montecchi-Palmer et al., 2017</xref>). The cognate TGFβ1 isoform induces similar fibrotic responses in fibroblasts, epithelial, and endothelial cells from heart, kidney, skin, and/or lung, suggesting induction of conserved fibrogenic programs (<xref ref-type="bibr" rid="bib19">Coker et al., 1997</xref>; <xref ref-type="bibr" rid="bib86">Santiago et al., 2005</xref>; <xref ref-type="bibr" rid="bib116">Yue et al., 2017</xref>; <xref ref-type="bibr" rid="bib119">Zhang et al., 2020</xref>). However, the contribution to OHT by ocular TGFβ expression cannot be disambiguated from the changing biomechanical environment: TGFβ release is activated by tissue contractility and tension (<xref ref-type="bibr" rid="bib102">Walker et al., 2020</xref>; <xref ref-type="bibr" rid="bib109">Wipff et al., 2007</xref>), and TGFβ activity correlates with mechanical stress gradients which may drive a cellular epithelial–mesenchymal transition-like phenotype (EMT; <xref ref-type="bibr" rid="bib122">Zhen et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Cabrera-Benítez et al., 2012</xref>; <xref ref-type="bibr" rid="bib104">Wei and Yang, 2016</xref>).</p><p>Despite its clinical relevance, our understanding of TM mechanotransduction and its contribution to IOP homeostasis remains rudimentary. Strain and shear stress have been hypothesized to engage primary cilia and integrins, as well as mechanosensitive TRPV4, Piezo1, and TREK-1 channels (<xref ref-type="bibr" rid="bib57">Luo et al., 2014</xref>; <xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib112">Yang et al., 2022</xref>; <xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>), yet it remains unclear whether these mechanosensors regulate TM contractility, are influenced by POAG inducers like TGFβ2 or glucocorticoids, or contribute to chronic fibrosis. Among these, TRPV4 (Transient Receptor Potential Vanilloid isoform 4), a tetrameric channel with P<sub>Ca</sub>/P<sub>Na</sub> ~ 10 (<xref ref-type="bibr" rid="bib107">White et al., 2016</xref>, <xref ref-type="bibr" rid="bib79">Redmon et al., 2018</xref>), is strongly expressed in rodent and human TM (<xref ref-type="bibr" rid="bib57">Luo et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Lapajne et al., 2022</xref>) where it carries the principal component of the pressure-activated transmembrane current and is activated by stretch, shear, and swelling (<xref ref-type="bibr" rid="bib70">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">Baumann et al., 2024</xref>; <xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>; <xref ref-type="bibr" rid="bib45">Katari et al., 2021</xref>). Pharmacological inhibition of the TRPV4 channel and deletion of the <italic>Trpv4</italic> gene alter pressure gradients in the brain, kidney, lung, and bladder (<xref ref-type="bibr" rid="bib21">Daneva et al., 2021</xref>; <xref ref-type="bibr" rid="bib74">Pochynyuk et al., 2013</xref>; <xref ref-type="bibr" rid="bib82">Roberts et al., 2020</xref>; <xref ref-type="bibr" rid="bib79">Redmon et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Toft-Bertelsen et al., 2022</xref>). TRPV4 mutations underpin sensorimotor neuropathies, skeletal dysplasias, retinal degeneration, and ocular dysfunction (<xref ref-type="bibr" rid="bib64">Nilius and Voets, 2013</xref>; <xref ref-type="bibr" rid="bib97">Thibodeau et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Klein et al., 2011</xref>), while the role of TRPV4 signaling in OHT remains contentious, with evidence suggesting both IOP-lowering and IOP-elevating effects. TRPV4 dependence of conventional outflow has been linked to diverse downstream effector mechanisms (e.g., endothelial nitric oxide synthase [eNOS] and RhoA activation, phospholipid–cholesterol–caveolin regulation, OCRL inositol-5-phosphatase interaction, modulation of cell–ECM contacts, polyunsaturated fatty acid (PUFA) release, and Piezo1 signaling; <xref ref-type="bibr" rid="bib70">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>; <xref ref-type="bibr" rid="bib79">Redmon et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Lakk et al., 2021</xref>; <xref ref-type="bibr" rid="bib100">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Jing et al., 2024</xref>; <xref ref-type="bibr" rid="bib83">Ryskamp et al., 2011</xref>) and thus leads toward testable hypotheses: if TM-intrinsic TRPV4 sustains steady-state normotension, promotes outflow via eNOS-dependent TM relaxation, and mitigates TGFβ2-driven fibrosis (<xref ref-type="bibr" rid="bib70">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Lakk et al., 2021</xref>), TRPV4 inhibition should induce OHT. Conversely, if TRPV4 activity exacerbates OHT, its blockade and deletion should reduce IOP.</p><p>In this study, we tested these hypotheses through investigation of reciprocal TRPV4–TGFβ2 interactions that perpetuate the vicious feedback loop between mechanical stressors, TM contractility, and OHT. We demonstrate that inhibition and deletion of TRPV4 lower IOP in TGFβ2 overexpression-induced and circadian OHT models and suppress TM contractility in TGFβ2-treated biomimetic hydrogels. The cytokine promoted upregulation of EMT-associated genes alongside increased transcription and activity of TRPV4, potentially sensitizing TM cells to physiological mechanical cues. Although TRPV4 activity was required to maintain OHT under physiological (nocturnal) and pathological (cytokine-induced) conditions, their respective IOP elevations were not additive, suggesting convergence on a shared common pathway that converges at the TRPV4 effector. Collectively, these findings position TRPV4 as a critical nexus of TGFβ2-induced TM contractility and IOP dysregulation. As such, TRPV4 perpetuates the vicious feedback loop between mechanical stressors and TM contractility and thus represents an ideal therapeutic target in glaucoma cases that resist current treatments.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TGFβ2 drives overexpression of genes that encode fibrotic markers and mechanosensitive ion channels</title><p>Human TM cells respond to TGFβ2 with increased biosynthesis, deposition and degradation of ECM, altered autophagy, upregulation of F-actin stress fibers, α-smooth muscle actin (<xref ref-type="bibr" rid="bib55">Li et al., 2022b</xref>; <xref ref-type="bibr" rid="bib25">Fleenor et al., 2006</xref>; <xref ref-type="bibr" rid="bib62">Montecchi-Palmer et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Nettesheim et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Li et al., 2022a</xref>), but it is unclear whether cells undergoing TGFβ2-induced fibrotic remodeling also exhibit altered capacity for sensing and transduction of mechanical stimuli. We thus profiled genes that encode known TM mechanochannels together with a selection of key cytoskeletal, ECM, and fibrotic markers in primary TM cells (pTM) isolated from three to seven donors without history of visual dysfunction (<xref ref-type="fig" rid="fig1">Figure 1A–C</xref>). Five-day exposure of pTM cells to a physiological concentration of TGFβ2 (1 ng/ml) increased the expression of EMT-promoting transcription factor SNAI1 (<italic>SNAIL1</italic>, p = 0.0094) and fibronectin (<italic>FN1</italic>, p = 0.0263), while expression of connective tissue growth factor <italic>2</italic> (<italic>CCN2</italic>, alternatively <italic>CTGF</italic>) was elevated in 5/5 pTM cell strains without reaching significance (p = 0.0909). Expression of fibroblast-specific protein 1 (<italic>FSP1</italic>, a calcium-binding fibroblast marker), yes-associated protein 1 (<italic>YAP1</italic>, a stiffness-induced hippo-pathway transcription factor), and <italic>ACTA2</italic> (αSMA<italic>,</italic> associated with cell contractility) was not consistently impacted by TGFβ2, while transcription of myocilin (<italic>MYOC</italic>) decreased across 4/4 pTM strains (p = 0.0055) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Indicative of feedback inhibition (<xref ref-type="bibr" rid="bib111">Yan et al., 2018</xref>), TGFβ2 treatment downregulated transcript levels of transforming growth factor beta receptor 2 (<italic>TGFBR2</italic>, p = 0.0219) and upregulated the expression of autoinhibitory SMAD family protein 7 (<italic>SMAD7</italic>, p = 0.0461) without affecting <italic>SMAD2</italic> or <italic>SMAD3</italic> expression. TGFβ2 thus promotes selective upregulation of ECM and fibrosis-related genes together with cell dedifferentiation and activation of autoregulatory SMAD mechanisms.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>TGFβ2 induces a fibrotic phenotype in primary trabecular meshwork (pTM) cells and increases expression and membrane insertion of the TRPV4 channel.</title><p>(<bold>A, B</bold>) Five-day TGFβ2 treatment (1 ng/ml) significantly altered expression of TGFβ pathway effectors, cytoskeletal machinery, and canonical fibrotic markers. (<bold>C</bold>) TGFβ2 treatment significantly increased <italic>TRPV4</italic> and <italic>PIEZO1</italic> expression, but not <italic>TREK1</italic> and <italic>TRPC1</italic> expression. Mean ± SEM shown. <italic>N</italic> = 4–8 experiments, each gene tested in 3–7 different pTM strains (see <xref ref-type="table" rid="table1">Table 1</xref>). Two-tailed one-sample <italic>t</italic>-test of TGFβ2-induced gene expression levels as a percent of control samples. (<bold>D</bold>) Isolation of membrane proteins from two separate pooled pTM samples suggests TGFβ2 treatment drives increased TRPV4 membrane insertion. <italic>N</italic> = 2 independent pooled samples, 3 pTM strains were pooled per sample. *p &lt; 0.05, **p &lt; 0.01.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Uncropped images of the membrane and HRP-signal for the western blots shown in <xref ref-type="fig" rid="fig1">Figure 1</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-104894-fig1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Uncropped images of the membrane and HRP-signal for the western blots shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-104894-fig1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>No significant difference was seen in (A) <italic>TRPV4</italic> or (B) <italic>PIEZO1</italic> expression between primary trabecular meshwork (pTM) samples treated with TGFβ2 (1 ng/ml) alone or TGFβ2 + TRPV4 antagonist HC-06 (5 µM) for 5 days.</title><p><italic>N</italic> = 3–4 independent experiments. Within each gene, symbols indicate paired samples. Wilcoxon matched-pairs signed rank test and paired <italic>t</italic>-test used, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Analysis of genes encoding mechanosensitive channels implicated in outflow modulation (<xref ref-type="bibr" rid="bib57">Luo et al., 2014</xref>; <xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Carreon et al., 2017</xref>; <xref ref-type="bibr" rid="bib113">Yarishkin et al., 2018a</xref>) showed a 102.5% increase in expression of <italic>TRPV4</italic> (p = 0.0193) and a 78.9% increase in <italic>PIEZO1</italic> expression (p = 0.0114) across eight replicates that included seven distinct pTM strains (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Conversely, TGFβ2 exposure did not affect expression of the <italic>TRPC1</italic> gene (p = 0.261) and had variable, strain-dependent effects on transcript levels <italic>of KCNK2 (</italic>p = 0.293, encoding the TREK-1 channel). Thus, TGFβ2 promotes selective transcriptional upregulation of genes that encode a subset of mechanosensitive proteins alongside fibrotic upregulation and cell dedifferentiation. Finally, we tested whether TGFβ2-induced upregulation of TRPV4 and Piezo1 is TRPV4 dependent. Inclusion of the selective TRPV4 inhibitor HC067-47 (HC-06; 5 mM), however, had no effect on transcriptional upregulation compared to TGFβ2 treatment alone (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p></sec><sec id="s2-2"><title>TGFβ2 exposure time-dependently augments TRPV4-mediated current and Δ[Ca<sup>2+</sup>]<sub>i</sub></title><p>To assess the functional relevance of TGFβ2-dependent transcriptional upregulation, we determined the membrane expression and functional activation of TRPV4, which mediates the pressure-activated current and calcium signaling, regulates cytoskeletal dynamics, and modulates conventional outflow resistance in vitro (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>). TGFβ2 exposure produces an increase in levels of membrane-bound TRPV4 protein (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) in western blot of two grouped pTM membrane protein samples. While low amounts of TRPV4 were visible in the membrane fractions in control samples, TGFβ2 treatment produced an increase in the higher weight TRPV4 band, suggesting there may be isoform-specific TGFβ2-induced responses and increased TRPV4 translation leading to elevated TRPV4 trafficking, membrane insertion, and/or lipid raft interaction (<xref ref-type="bibr" rid="bib49">Lakk et al., 2021</xref>).</p><p>Functional expression was assessed by tracking [Ca<sup>2+</sup>]<sub>i</sub> changes in cells exposed to the selective TRPV4 agonist GSK1016790A (GSK101, 10 nM) using ratiometric Fura2-AM Ca<sup>2+</sup> dye, with TGFβ2-treated and control cells tested on the same day. All pTM strains responded to GSK101 with robust [Ca<sup>2+</sup>]<sub>i</sub> increases which reached peak within 5 min and was followed by a gradual decrease to a steady plateau (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). TGFβ2-treated cells exhibited a remarkable potentiation of GSK101-evoked [Ca<sup>2+</sup>]<sub>i</sub> responses compared to control cells, with 5/5 cell strains showing an increase in the ∆peak/baseline <italic>F</italic><sub>340</sub>/<italic>F</italic><sub>380</sub> response equivalent to 258.4% ± 61.7% of the control response in (p = 0.0046) (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>). The fraction of GSK101 responders and the overall time course of responses between groups were not significantly different, indicating that TRPV4 potentiation primarily affects TRPV4-expressing cells. Thus, TGFβ2 treatment promotes TRPV4 expression and functional activity, presumably to increase their sensitivity to mechanical stressors (<xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TRPV4-mediated Ca<sup>2+</sup> influx is potentiated by 5-day TGFβ2 treatment.</title><p>(<bold>A</bold>) Five-day TGFβ2 treatment (1 ng/ml) increased TRPV4 agonist-induced (GSK101, 10 nM) Ca<sup>2+</sup> influx in primary trabecular meshwork (pTM) cells compared to serum-free media alone treated cells tested on the same day (<italic>N</italic> = 5 pTM strains, <italic>n</italic> = 3–5 slides/condition/day, individual data points over mean ± SEM). Two-tailed one-sample <italic>t</italic>-test of TGFβ2-treated cell average GSK101 response as a percent of control samples from the same pTM strain on the same day. (<bold>B</bold>) Violin plots showing the distribution of GSK101-induced Ca<sup>2+</sup> responses for each pTM strain tested in A. Thick dashed line indicates mean, while light dashed line indicates quartiles. (<bold>C</bold>) Representative traces showing TRPV4 agonist-induced Ca<sup>2+</sup> influx (seen as an increase in <italic>F</italic><sub>340</sub>/<italic>F</italic><sub>380</sub>) in pTM (mean ± SEM of 4 representative cells/group), alongside example Fura-2-loaded pTM cells before (<bold>i</bold>), during (<bold>ii</bold>), and after (<bold>iii</bold>) GSK101 application. Scale bar = 50 µm. **p &lt; 0.01.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig2-v1.tif"/></fig><p>To gain insight into the time- and dose-dependence of TGFβ2-dependent TRPV4 signaling modulation, pTM cells were treated for 24 hr, at 1 and 5 ng/ml concentrations of TGFβ2. GSK101-stimulated Ca<sup>2+</sup> influx was not significantly increased by 24 hr TGFβ2 treatment at 1 ng/ml (∆peak/baseline <italic>F</italic><sub>340</sub>/<italic>F</italic><sub>380</sub> = 117.0% ± 23.6% of control) or 5 ng/ml (∆peak/baseline <italic>F</italic><sub>340</sub>/<italic>F</italic><sub>380</sub> = 133.6% ± 34.5% of control) <xref ref-type="fig" rid="fig3">Figure 3</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; the potentiation of both was significantly lower relative to the 1-day 1 ng/ml TGFβ2 treatment (p &lt; 0.0011; <xref ref-type="fig" rid="fig3">Figure 3A</xref>). GSK101 evoked a moderately outwardly rectifying nonselective current (<italic>I</italic><sub>GSK</sub> − <italic>I</italic><sub>baseline</sub>) with reversal potential at ~0 mV (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). While its amplitude was variable, mean current density consistently increased in cells treated for 1 day with TGFβ2 (<italic>n</italic> = 10; 5 ng/ml) relative to the control group (<italic>n</italic> = 11). The potentiating effect of TGFβ2 on TRPV4 activity appears to be time dependent, reaching significance after chronic exposure to relatively low-dose TGFβ2.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>TGFβ2-induced TRPV4 potentiation is not seen at a shorter period, regardless of treatment strength.</title><p>(<bold>A</bold>) TGFβ2 treatments for 24 hr at 1 ng/ml (<italic>N</italic> = 6 pTM strains, <italic>n</italic> = 3–5 slides/condition/day) or 5 ng/ml (<italic>N</italic> = 5 pTM strains, <italic>n</italic> = 3–5 slides/condition/day) did not show potentiation of GSK101-evoked TRPV4 Ca<sup>2+</sup> influx (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) and were significantly lower than cells treated with TGFβ2 for 5 days at 1 ng/ml (5 days TGFβ2 results from <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Individual data points over mean ± SEM. One-way ANOVA with Tukey’s multiple comparisons test, statistics for individual 1 day treatment groups compared to control groups shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. (<bold>B</bold>) Representative traces for GSK101 response following 24 hr TGFβ2 treatment, traces show mean ± SEM of 3–4 cells. (<bold>C</bold>) Average current density in response to GSK101 (24 hr control: <italic>n</italic> = 11 cells, 24 hr TGFβ2: <italic>n</italic> = 10 cells) shows generally increased current in TGFβ2-treated cells. Data show mean ± SEM (<bold>D, E</bold>). Violin plots of individual cell strains shown in <bold>A</bold>. Thick dashed line indicates mean, while light dashed line indicates quartiles. <italic>**</italic>p <italic>&lt;</italic> 0.01, <italic>***</italic>p <italic>&lt;</italic> 0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>TGFβ2 concentrations of 1 ng/ml (<bold>A</bold>) and 5 ng/ml (<bold>B</bold>) did not significantly increase TRPV4-induced calcium influx with respect to control cells.</title><p>Individual statistical analysis of experiments shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref> (1 ng/ml: p = 0.138, 5 ng/ml: p = 0.095), one sample <italic>t</italic>-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>TGFβ2-induced TM contractility requires TRPV4 activation</title><p>The IOP-lowering effectiveness of Rho kinase inhibitors and latrunculins (<xref ref-type="bibr" rid="bib54">Li et al., 2022a</xref>; <xref ref-type="bibr" rid="bib35">Honjo, 2001</xref>; <xref ref-type="bibr" rid="bib76">Rao et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Ethier et al., 2006</xref>) indicates that sustained increases in outflow resistance require tonic actin polymerization and contractility. TGFβ2 drives the TM myofibroblast contractile response (<xref ref-type="bibr" rid="bib54">Li et al., 2022a</xref>), while the role of mechanosensation remains unknown. To ascertain whether TRPV4 upregulation (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>) contributes to the contractile response, we seeded pTM cells into high-compliance type I collagen hydrogels (<xref ref-type="bibr" rid="bib54">Li et al., 2022a</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>). Hydrogels that were incubated with TGFβ2 (5 ng/ml) exhibited marked increases (p &lt; 0.0003) in the rate and the magnitude of contraction at all time points (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>). Simultaneous treatment with HC-06 (5 µM) significantly reduced the extent of TGFβ2-induced TM contractility (p &lt; 0.0001). To determine whether TRPV4 activation is sufficient to induce the contractile response, the antagonist was washed out and hydrogels supplemented with GSK101 (25 nM). Fifteen minutes post-treatment, the constructs responded to the agonist with transient contraction (<xref ref-type="fig" rid="fig4">Figure 4C</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, p &lt; 0.01), with a time course mirroring GSK101-induced [Ca<sup>2+</sup>]<sub>i</sub> elevations (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). The effects of TRPV4 inhibition and activation were consistent across all pTM strains tested (<italic>N</italic> = 3). TRPV4-mediated Ca<sup>2+</sup> influx is therefore sufficient to induce TM contractility and necessary for pTM hypercontractility induced by TGFβ2.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Effects of TRPV4 inhibition/activation on TGFβ2-induced contraction of trabecular meshwork (TM) cells.</title><p>(<bold>A</bold>) Representative longitudinal 24-well plate scans of collagen type I hydrogels seeded with primary TM (pTM) subjected to the different treatments (dashed lines outline size of contracted constructs). (<bold>B</bold>) Longitudinal quantification of hydrogel construct size compared to the control group at the 0 min time point. (<bold>C</bold>) Detailed comparisons between groups at each experimental time point. <italic>n</italic> = 6 hydrogels/group. One-way ANOVA with Tukey’s multiple comparisons test, data in (<bold>B, C</bold>) show individual data points over mean ± SD. One pTM strain shown: TGFβ2-induced contractility induction, HC-06-mediated rescue of hypercontractility, and GSK101-induced transient (15 min) contraction were consistent across (3/3) pTM strains tested (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>TRPV4 activation is obligatory for TGFβ2-induced trabecular meshwork (TM) cell contractions.</title><p>(<bold>A, D</bold>) Representative longitudinal 24-well plate scans of collagen type I hydrogels seeded with two distinct primary TM (pTM) strains (pTM 1: <bold>A–C</bold>, pTM 2: <bold>D–F</bold>) subjected to the different treatments as in <xref ref-type="fig" rid="fig4">Figure 4</xref>. (<bold>B, E</bold>) Longitudinal quantification of hydrogel construct size. (<bold>C, F</bold>) Detailed comparisons between groups at each experimental time point (<italic>N</italic> = 6 experimental replicates/pTM strain). One-way ANOVA with Tukey multiple comparisons test, data in (<bold>B, D</bold>) show individual data points over mean ± SEM. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Detailed view of primary trabecular meshwork (pTM) seeded collagen constructs used in <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title><p>High-resolution representative image of collagen gels used for contractility experiments without a circle around the periphery of the gel.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig4-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>TRPV4 activity is required to maintain TGFβ2-induced OHT</title><p>To test whether TRPV4 contributes to TGFβ2-induced OHT in vivo, we utilized the lentiviral TGFβ2 overexpression model developed by <xref ref-type="bibr" rid="bib71">Patil et al., 2022</xref> in which adult C57BL/6J mice (<italic>N</italic> = 5) were intravitreally injected with lentivirus overexpressing constitutively active human TGFβ2 (LV-TGFβ2). LV-TGFβ2-injected eyes, but not the contralateral eyes injected with a lentivirus containing a scrambled transgene (LV-Ctrl), exhibited significant IOP elevations 1-week post-transduction (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, Week 2, Δ<sub>TGF-Ctrl</sub> = 4.0 mm Hg, p = 0.0143). By 2 weeks post-transfection, IOP in LV-TGFβ2 eyes reached 19.9 ± 4.7 mm Hg, whereas IOP in LV-Control eyes remained at control levels (14.0 ± 1.2 mm Hg), with Δ<sub>TGF-Ctrl</sub> = 5.9 mm Hg (p = 0.0002). IOP remained elevated throughout the 4 weeks after the injection (Week 5, Δ<sub>TGF-Ctrl</sub> = 4.9 mm Hg, p = 0.0008). HC-06 (100 µM) microinjection into the anterior chamber of LV-TGFβ2 and LV-Ctrl eyes lowered IOP in LV-TGFβ2 eyes to 12.2 ± 1.7 mm Hg after 24 hr (Δ<sub>postHC-preHC</sub> = −5.8 mm Hg) with no difference observed in IOP from LV-Ctrl eyes (12.6 ± 1.9 mm Hg, Δ<sub>postHC-preHC</sub> = −0.3 mm Hg). LV-Ctrl eyes remained close to pre-injection levels post-HC-06 treatment (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>). IOP in LV-TGFβ2 eyes returned to hypertensive levels by 1 week post-HC-06 injection (Weeks 6 and 7, Δ<sub>TGF-Ctrl</sub> = 3.9 mm Hg, p = 0.0201). To determine the effect of the bolus injection alone, LV-TGFβ2 and LV-Ctrl eyes were reinjected with PBS 2 weeks after re-establishing the OHT baseline. The sham injection transiently reduced IOP in LV-TGFβ2 (Δ<sub>postPBS-prePBS</sub> = −4.5 mm Hg) and LV-Ctrl (Δ<sub>postPBSpre-PBS</sub> = −1.2 mm Hg) eyes; however, LV-TGFβ2 eyes returned to hypertensive levels by 48 hr post-injection (Δ<sub>TGF-Ctrl</sub> = 3.6 mm Hg, p = 0.0465) and to pre-injection levels after 72 hr (Δ<sub>TGF-Ctrl</sub> = 5.4 mm Hg, p = 0.0002). Bolus injection was less effective than HC-06 at all time points 24 hr post-injection (Weeks 8 and 9, <xref ref-type="fig" rid="fig5">Figure 5B</xref>). These data indicate that selective pharmacological inhibition of TRPV4 effectively and reversibly blocks TGFβ2-induced OHT.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TRPV4 activation is necessary to maintain LV-TGFβ2-induced ocular hypertension (OHT).</title><p>(<bold>A</bold>) Intravitreal injection of LV-TGFβ2 (Week 1), but not LV-Control, elevates intraocular pressure (IOP) in WT mice (<italic>N</italic> = 5 eyes/group) as early as 1-week post-injection. Injection of TRPV4 antagonist HC-06, but not PBS, produced multiday IOP reduction in LV-TGFβ2-treated eyes. HC-06 and PBS injections did not affect IOP in LV-Control injected eyes. Two-way ANOVA with Bonferroni post hoc analysis (<bold>B</bold>) Direct comparison of the results of PBS and HC-06 injections in the eyes shown in <bold>A</bold>. Two-way ANOVA with Bonferroni post hoc analysis. (<bold>C</bold>) Intravitreal injection of LV-TGFβ2 in <italic>Trpv4<sup>−/−</sup></italic> mice (<italic>N</italic> = 6 eyes/group) resulted in only mild OHT; plotted against WT eyes at matching timepoints (3 WT cohorts including the 5 WT eyes shown in A, B, <italic>N</italic> = 8–15 eyes/group). (<bold>D</bold>) Statistical comparison of the IOP values shown in <bold>C</bold>. The IOP in LV-TGFβ2 WT eyes was significantly elevated compared to the LV-TGFβ2 <italic>Trpv4<sup>−/−</sup></italic> eyes from 2 weeks post-injection. LV-Control injected eyes in WT or <italic>Trpv4<sup>−/−</sup></italic> eyes remain close to the baseline value and are not significantly different. Two-way ANOVA with Bonferroni post hoc analysis. (<bold>A, C</bold>) shows mean ± SEM. Data in (<bold>B, D</bold>) show individual data points over mean ± SEM, *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for Lv-Control IOP and Lv-TFFb2 cohorts treated with HC-06.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-104894-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Source data for IOP data from WT and Trpv4 KO eyes treated with TGFβ2.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-104894-fig5-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Expansion of <xref ref-type="fig" rid="fig5">Figure 5D</xref><italic>.</italic></title><p>Intraocular pressure (IOP) in LV-TGFβ2-injected eyes was significantly elevated compared to both LV-Ctrl injected WT and <italic>Trpv4</italic><sup>−/−</sup> eyes, as well as LV-TGFβ2-injected <italic>Trpv4</italic><sup>−/−</sup> eyes (<italic>N</italic> = 6 eyes/condition).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig5-figsupp1-v1.tif"/></fig></fig-group><p>To further evaluate the TRPV4 dependence of TGFβ-induced OHT, we took advantage of mice with global <italic>Trpv4</italic> knockdown (<xref ref-type="bibr" rid="bib56">Liedtke and Friedman, 2003</xref>; <xref ref-type="bibr" rid="bib83">Ryskamp et al., 2011</xref>; <xref ref-type="bibr" rid="bib114">Yarishkin et al., 2018b</xref>). <italic>Trpv4<sup>−/−</sup></italic> mice (<italic>N</italic> = 6) were injected with LV-TGFβ2 and LV-Ctrl vectors in contralateral eyes (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Additionally, two littermate control mice injected alongside the <italic>Trpv4<sup>−/−</sup></italic> animals were added to previously collected WT LV-injected cohorts measured at the same timepoints (<italic>N</italic> = 8–15, <xref ref-type="fig" rid="fig5">Figure 5C</xref>). Pre-LV injection, IOP levels in <italic>Trpv4</italic><sup>−/−</sup> animals were comparable to the WT cohort, indicating that TRPV4 activity does not regulate normotension. Similarly, IOP in LV-Ctrl-injected eyes was not significantly different between WT and <italic>Trpv4<sup>−/−</sup></italic> animals at any point in the experiment (peak Δ<sub>CtrlKO-CtrlWT</sub> = −1.2 mm Hg, <xref ref-type="fig" rid="fig5">Figure 5D</xref><italic>,</italic> <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). By 2 weeks post-injection (Week 3), LV-TGFβ2-treated <italic>Trpv4</italic><sup>−/−</sup> eyes exhibited significantly lower IOP compared to the LV-TGFβ2 WT cohort (Δ<sub>TGFKO-TGFWT</sub> = −3.1 mm Hg, p = 0.0009, <xref ref-type="fig" rid="fig5">Figure 5C</xref>). LV-TGFβ2 injected <italic>Trpv4<sup>−/−</sup></italic> eyes exhibited mild OHT but the effect was significantly reduced compared to WT eyes, and IOP decreased by 2 weeks post-injection (<xref ref-type="fig" rid="fig5">Figure 5C, D</xref>).</p></sec><sec id="s2-5"><title>TGFβ2-induced and nocturnal OHT are non-additive but require TRPV4</title><p>Mammalian IOP is modulated by the circadian rhythm, with levels elevated at night and nocturnal IOP fluctuations implicated in POAG (<xref ref-type="bibr" rid="bib70">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="bib80">Redmon et al., 2024</xref>; <xref ref-type="bibr" rid="bib36">Ikegami and Masubuchi, 2022</xref>). We measured nocturnal (9:00–10:00 PM) IOP in LV-TGFβ2 (<italic>N</italic> = 4) and LV-Ctrl WT eyes (<italic>N</italic> = 4) from isoflurane-anesthetized mice ~2 months post-LV injection to determine whether nocturnal OHT is additive to TGFβ2-induced elevation observed during the daytime (12:00–2:00 PM, <xref ref-type="fig" rid="fig6">Figure 6A</xref>). LV-TGFβ2 injected eyes showed significant IOP elevation compared to LV-Ctrl eyes during daytime measurements (diurnal Δ<sub>TGFβ-Ctrl</sub> = 7.9 mm Hg, p &lt; 0.0001) but the difference vanished at night (nocturnal Δ<sub>TGFβ-Ctrl</sub> = 0.2 mm Hg), indicating that TGFβ2-induced OHT is not additive to the circadian OHT. To test whether the IOP measurement was influenced by isoflurane-induced anesthesia, we repeated the nocturnal measurements in awake animals (<italic>N</italic> = 4–6 eyes/group). We observed no difference in nocturnal IOP between the two groups of animals was observed (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref><italic>,</italic> <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). To determine whether physiological (nocturnal) OHT requires TRPV4, we microinjected LV-Ctrl (<italic>N</italic> = 4) and hypertensive LV-TGFβ2 (<italic>N</italic> = 4) eyes with PBS or HC-06. PBS injection did not affect IOP in LV-Ctrl or LV-TGFβ2 eyes at day or night (<xref ref-type="fig" rid="fig6">Figure 6E, F</xref>) except for a single LV-TGFβ2 eye that exhibited abnormally high nocturnal IOP (37 mm Hg) at the 4-day timepoint. Conversely, HC-06 injection blocked LV-TGFβ2-induced IOP during the day (<italic>P</italic>&lt;0.001) and significantly lowered IOP in LV-Ctrl and LV-TGFβ2 eyes at night (~5 mm Hg; p &lt; 0.01). These data indicate that (1) TRPV4 activation is necessary for OHT in the TGFβ2 overexpression mouse model (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>) and the circadian IOP elevations, (2) TGFβ2-evoked OHT does not affect nocturnal IOP elevation in mice, and (3) TRPV4 inhibition does not disrupt the mechanisms that maintain daytime normotensive IOP (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>TRPV4 inhibition inhibits nocturnal intraocular pressure (IOP) elevation in control and TGFβ2 overexpressing eyes.</title><p>(<bold>A, B</bold>) Post-LV injection daytime (12–2:00 P.M) and nocturnal (9–10:00 P.M.) IOP compared in WT mice (<italic>N</italic> = 4–6 eyes/group) before drug treatment. LV-TGFβ2 eyes were elevated at daytime, but nocturnal ocular hypertension (OHT) was not significantly different between LV-Ctrl and LV-TGFβ2 eyes in two separate cohorts of mice measured under isoflurane anesthesia (<bold>A</bold>) or while awake (<bold>B</bold>). (<bold>C, D</bold>) Anesthesia had no significant effect on measured nocturnal IOP. One-way ANOVA with Tukey’s multiple comparisons test. (<bold>E, F</bold>) PBS-injected eyes did not exhibit changes in daytime or nighttime intraocular pressure; however, HC-06 injection reduced TGFβ2-induced IOP elevations during the day and LV-Ctrl and LV-TGFβ2 nocturnal IOPs (<italic>N</italic> = 4 eyes/group); two-way ANOVA with Bonferroni post hoc analysis. Figures show data points over mean ± SEM, *p &lt; 0.05<italic>, **</italic>p &lt; 0.01, ****p &lt; 0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data for nocturnal and diurnal IOP cohorts from control mice and animals treated with LV-TGFβ2.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-104894-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Nocturnal intraocular pressure (IOP) is not significantly affected by LV-TGFβ2 overexpression.</title><p>Expanded time series of IOP measured weekly from a second cohort of mouse eyes (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) injected with LV-Ctrl (<italic>n</italic> = 6 eyes) or LV-TGFβ2 (<italic>n</italic> = 4 eyes). LV-TGFβ2 resulted in elevated diurnal IOP, which gradually approached the IOP seen in nocturnal measurements but did not further elevate IOP above nocturnal values. In this cohort, both diurnal and nocturnal measurements were made in awake animals.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig6-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study establishes a mechanistic framework that integrates biochemical and biomechanical risk factors of POAG and highlights the pivotal role of TRPV4, a polymodal Ca<sup>2+</sup>-permeable channel, as a key regulator of TM contractility and OHT. Our central finding is that the glaucoma-inducing cytokine TGFβ2 amplifies TRPV4 expression and activity, which in turn drives tonic increases in TRPV4 activation and TM contractility that are required to maintain elevated IOP. These observations position the pressure-activated channel (<xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>) as a molecular linchpin that links mechanical stress to neurodegeneration resulting from the obstruction of the primary outflow pathway. Our confirmation of the linkage between TGFβ signaling and TRPV4 in TM links POAG pathophysiology to fibrotic remodeling seen in other tissues (<xref ref-type="bibr" rid="bib75">Rahaman et al., 2014</xref>; <xref ref-type="bibr" rid="bib108">Willard et al., 2021</xref>). Considering that current glaucoma treatments target secondary outflow mechanisms or incur side effects (such as hyperemia) (<xref ref-type="bibr" rid="bib88">Sharif, 2023</xref>; <xref ref-type="bibr" rid="bib105">Weinreb et al., 2002</xref>), the IOP lowering achieved through TRPV4 inhibition and gene knockdown promises a novel therapeutic avenue to mitigate ocular injury.</p><p>The etiology of glaucoma reflects convergence of risk factors that include IOP and TGFβ2: epidemiological data correlate the incidence of POAG with the amplitude of IOP and [TGFβ2]<sub>AH</sub> (<xref ref-type="bibr" rid="bib99">Tripathi et al., 1994</xref>; <xref ref-type="bibr" rid="bib53">Leske et al., 2003</xref>), while chronic increases of either [TGFβ2]<sub>i</sub> or IOP promote fibrotic remodeling of TM/SC and augment the flow resistance of the conventional pathway (<xref ref-type="bibr" rid="bib28">Fuchshofer and Tamm, 2012</xref>; <xref ref-type="bibr" rid="bib91">Shepard et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Fleenor et al., 2006</xref>). TGFβ2-induced facility suppression has been historically attributed to changes in composition, crosslinking, and amount of ECM (<xref ref-type="bibr" rid="bib25">Fleenor et al., 2006</xref>; <xref ref-type="bibr" rid="bib62">Montecchi-Palmer et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Fuchshofer et al., 2005</xref>; <xref ref-type="bibr" rid="bib61">Medina-Ortiz et al., 2013</xref>), activation of Hippo signaling and Rho kinase- (Rho/ROCK) mediated contractility (<xref ref-type="bibr" rid="bib55">Li et al., 2022b</xref>; <xref ref-type="bibr" rid="bib54">Li et al., 2022a</xref>) and altered expression of genes encoding mitogen-activated protein kinase, immune response, oxidative stress, and/or ECM pathways (<xref ref-type="bibr" rid="bib15">Callaghan et al., 2022</xref>; <xref ref-type="bibr" rid="bib38">Inoue-Mochita et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Kang et al., 2013</xref>). Our discovery reveals that such biochemical mechanisms engage in bidirectional interplay with biomechanical factors and transducers: TGFβ2 impacts the expression and function of TM mechanosensors and vice versa, TRPV4 is required for TGFβ2-induced contractility. Specifically, we found that TGFβ2 (1) induced time-dependent upregulation of TRPV4 mRNA and amplified TRPV4-mediated calcium signaling, while (2) TRPV4 was required to mediate TGFβ2-induced TM hypercontractility and maintain chronic OHT in TGFβ2-treated mouse eyes. Microinjection of the selective antagonist HC-06 accordingly reduced IOP in LV-TGFβ2-treated eyes to baseline with hypotension persisting for ~4 days and reversing to pre-injection OHT by day 7. The TRPV4 dependence of TGFβ2-induced OHT and contractility was corroborated in <italic>Trpv4</italic><sup>−/−</sup> mice and in vitro using TGFβ2-treated 3D hydrogel constructs. In vivo, pharmacological inhibition (~100% reduction in OHT, transient) outperformed gene knockdown (~50% reduction in OHT, stable), potentially due to compensatory mechanosensory mechanisms in Trpv4-<italic>null</italic> animals (<xref ref-type="bibr" rid="bib80">Redmon et al., 2024</xref>).</p><p>We’ve previously shown that TM TRPV4 is activated by physiological (5–25 mm Hg) pressure steps (<xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>; <xref ref-type="bibr" rid="bib113">Yarishkin et al., 2018a</xref>) and (1–12%) strains (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>), which trigger downstream outflow-relevant signaling through Rho kinase, F-actin, tyrosine phosphorylation of FAK, paxillin and vinculin, lipid remodeling, and ECM release mechanisms (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>; <xref ref-type="bibr" rid="bib49">Lakk et al., 2021</xref>). The present study extends those observations by revealing the TRPV4 -dependence of TM contractility (the agonist GSK101 induced, and the antagonist HC-06 suppressed, contractility in a 3D biomimetic model) and by establishing TRPV4 as an obligatory effector of OHT under physiological (circadian rhythmicity) as well as pathological conditions. These findings resolve conflicting reports of hypotensive vs. hypertensive effects of TRPV4 modulation (<xref ref-type="bibr" rid="bib70">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Luo et al., 2014</xref>; <xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>; <xref ref-type="bibr" rid="bib49">Lakk et al., 2021</xref>; <xref ref-type="bibr" rid="bib100">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib80">Redmon et al., 2024</xref>). While TRPV4 activity has been suggested to lower IOP via phosphoinositide signaling in primary cilia (<xref ref-type="bibr" rid="bib57">Luo et al., 2014</xref>), TM-resident eNOS activity (<xref ref-type="bibr" rid="bib70">Patel et al., 2021</xref>), release of PUFAs (<xref ref-type="bibr" rid="bib100">Uchida et al., 2021</xref>), and/or signaling downstream from Piezo1 mechanosensing (<xref ref-type="bibr" rid="bib39">Jing et al., 2024</xref>), these mechanisms are challenged by evidence that TRPV4-regulated Ca<sup>2+</sup> influx persists in TM cells with ablated primary cilia (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>), eNOS expression in TM cells is vanishingly low (<xref ref-type="bibr" rid="bib81">Reina-Torres et al., 2021</xref>; <xref ref-type="bibr" rid="bib101">van Zyl et al., 2020</xref>), PUFAs such as arachidonic acid and epoxyeicosatrienoic acids stimulate rather than inhibit TRPV4 (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>), and TRPV4 signaling in TM cells is unaffected by Piezo1 inhibition and knockdown (<xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>). Rather, the suppression of outflow facility by Piezo1 inhibitors in vitro and in vivo (<xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>; <xref ref-type="bibr" rid="bib123">Zhu et al., 2021</xref>) suggests that Piezo1 opposes the hypertensive functions of TRPV4.</p><p>The TRPV4 dependence of outflow resistance is indicated by multiple lines of evidence. In biomimetic human TM scaffolds that support flow devoid of ciliary body or SC influences, TRPV4 inhibition enhanced, and activation suppressed, the facility (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>). We demonstrated that the agonist (GSK101) induces contractility while the antagonist (HC-06) mitigated TGFβ2-induced hypercontractility and lowered IOP in TGFβ2-overexpressing eyes. These results support a model wherein TGFβ2 augments TRPV4-mediated pressure transduction to drive hypercontractility and fibrosis via Ca<sup>2+</sup>- and Rho-dependent stress fiber formation and reinforcement of focal ECM contacts (<xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>; <xref ref-type="bibr" rid="bib72">Pattabiraman et al., 2015</xref>; <xref ref-type="bibr" rid="bib117">Zhang et al., 2008a</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>). Taking into account TRPV4 thermosensitivity (Q<sub>10</sub> of ~10, with peak activation at physiological temperature of ~34–37°C; <xref ref-type="bibr" rid="bib33">Güler et al., 2002</xref>; ; <xref ref-type="bibr" rid="bib65">Nishimoto et al., 2021</xref>), TGFβ2-induced contractility of TM-populated hydrogels may reflect the synergy between severalfold transcriptional and functional amplification of TRPV4-mediated signaling (<xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig3">3</xref>) and constitutive temperature-facilitated activation of TRPV4. These synergistic effects were unmasked as the absence of hypercontractility in samples treated with HC-06. The residual contractility in HC-06-treated cells could reflect contributions from Piezo1, TRPC, and/or TREK-1 channels (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib113">Yarishkin et al., 2018a</xref>; <xref ref-type="bibr" rid="bib1">Abad et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Feger et al., 2017</xref>). Parallels from studies conducted on heart, lung, liver, skin, and articular cartilage similarly found that TRPV4 contributes to the progression of fibrosis induced by the cognate TGFβ1 cytokine (<xref ref-type="bibr" rid="bib75">Rahaman et al., 2014</xref>; <xref ref-type="bibr" rid="bib89">Sharma et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Adapala et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">O’Conor et al., 2014</xref>; <xref ref-type="bibr" rid="bib93">Song et al., 2014</xref>) and implicated the TRPV4 channel in the contractility of the bladder (<xref ref-type="bibr" rid="bib110">Wu et al., 2021</xref>), heart (<xref ref-type="bibr" rid="bib42">Jones et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Chaigne et al., 2023</xref>), and blood vessels (<xref ref-type="bibr" rid="bib106">Wen et al., 2023</xref>) . Interestingly, conditional <italic>Trpv4</italic> ablation from smooth muscle cells lowered blood pressure (<xref ref-type="bibr" rid="bib18">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="bib124">Zhu et al., 2023</xref>), an effect not dissimilar from IOP lowering in <italic>Mgp:Trpv4</italic> cKO mice (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>TGFβ2–TRPV4 interactions in trabecular meshwork (TM) remodeling and ocular hypertension (OHT).</title><p>Chronic exposure to TGFβ2 induces upregulation of functional TRPV4 channels alongside the autoinhibitory canonical modulator SMAD7. TRPV4-mediated Ca<sup>2+</sup> influx, canonical, and non-canonical TGFβ2 signaling stimulate the Rho/ROCK pathway to augment cytoskeletal contractility and stimulate extracellular matrix (ECM) release. Actomyosin contractility promotes outflow resistance and drives OHT and underpins a vicious feedforward TRPV4-dependent loop that maintains OHT. This figure was created using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/umbwthh">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-fig7-v1.tif"/></fig><p>TGFβ2-induced upregulation of <italic>FN1</italic>, <italic>SNAIL1</italic>, and <italic>CTGF</italic> transcripts (<xref ref-type="fig" rid="fig1">Figure 1</xref>) accords with RNA profiling studies which cataloged the cytokine’s role in transdifferentiation of TM cells into contractile myofibroblasts (<xref ref-type="bibr" rid="bib25">Fleenor et al., 2006</xref>; <xref ref-type="bibr" rid="bib15">Callaghan et al., 2022</xref>; <xref ref-type="bibr" rid="bib120">Zhao et al., 2004</xref>; <xref ref-type="bibr" rid="bib121">Zhavoronkov et al., 2016</xref>; <xref ref-type="bibr" rid="bib52">Last et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Raychaudhuri et al., 2017</xref>; <xref ref-type="bibr" rid="bib78">Read et al., 2007</xref>; <xref ref-type="bibr" rid="bib103">Wang et al., 2017</xref>) whereas the decreased expression of the <italic>TGFΒR2</italic> gene and increased abundance of <italic>SMAD7</italic> mRNA indicate concurrent activation of autoinhibitory mechanisms associated with canonical TGFβ-family signaling (<xref ref-type="bibr" rid="bib27">Fuchshofer et al., 2009</xref>). The threefold increase in <italic>TRPV4</italic> transcription and responsiveness to GSK101 was observed at POAG-relevant TGFβ2 concentrations (in AH, ~0.2–3.2 ng/ml; <xref ref-type="bibr" rid="bib4">Agarwal et al., 2015</xref>), with a time course that mirrored facility reduction in human eyes treated with exogenous cytokine (<xref ref-type="bibr" rid="bib31">Gottanka et al., 2004</xref>). A single 5 ng/ml TGFβ2 dose was sufficient to double the amplitude of the GSK101-evoked current and alter its rectification (<xref ref-type="fig" rid="fig3">Figure 3</xref>), with imaging experiments confirming robust and reproducible increases in Ca<sup>2+</sup> signals across the 5/5 studied strains after 5 days of treatment (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The effects of TGFβ2 on <italic>I</italic><sub>TRPV4</sub>, membrane protein levels and [Ca<sup>2+</sup>]<sub>GSK</sub> accord with increased expression of the <italic>TRPV4</italic> gene. Precedents from other cell types (e.g., fibroblasts) suggest functional upregulation might involve increased trafficking of TRPV4–PI3Kγ complexes and/or β-arrestin 1-dependent ubiquitination (<xref ref-type="bibr" rid="bib32">Grove et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Shukla et al., 2010</xref>). The upregulation of <italic>TRPV4/PIEZO1</italic> transcription by TGFβ2 predicts exaggerated responsiveness of the outflow pathway to mechanical loading, as reported for TRPV4-dependent mechanical hyperalgesia in chemotherapy (<xref ref-type="bibr" rid="bib59">Matsumura et al., 2014</xref>), neuropathic pain (<xref ref-type="bibr" rid="bib118">Zhang et al., 2008b</xref>; <xref ref-type="bibr" rid="bib5">Alessandri-Haber et al., 2006</xref>), cancer (<xref ref-type="bibr" rid="bib58">Maqboul and Elsadek, 2018</xref>), and diabetic neuropathy (<xref ref-type="bibr" rid="bib20">Cui et al., 2020</xref>).</p><p>An important corollary of these findings is that they extend TRPV4’s role beyond pathology into the IOP homeostasis in healthy animals. TRPV4 inhibitors, ROCK inhibitors, and TM-specific expression of dominant negative scAAV2.<italic>dnRhoA</italic> constructs lower IOP across diverse OHT models (occlusion of the iridocorneal angle, TGFβ, glucocorticoids, and the nocturnal cycle; <xref ref-type="bibr" rid="bib80">Redmon et al., 2024</xref>; <xref ref-type="bibr" rid="bib76">Rao et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Borrás et al., 2015</xref>). The TRPV4 dependence and lack of additivity between physiological (circadian-induced) and pathological OHT modes (<xref ref-type="fig" rid="fig6">Figure 6</xref>) in untreated and TGFβ2 eyes imply convergence at the level of TRPV4-Rho signaling as the final effector of conventional outflow resistance. An interesting challenge for future studies will be elucidation of mechanisms that underlie the reversibility of circadian TRPV4 activation, which might combine testing involvement of the suprachiasmatic nucleus, the hypothalamus–pituitary–adrenal axis (<xref ref-type="bibr" rid="bib85">Samuels et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Ikegami, 2024</xref>), nocturnal release of norepinephrine and melatonin (<xref ref-type="bibr" rid="bib90">Shen et al., 1992</xref>; <xref ref-type="bibr" rid="bib95">Steinberg et al., 2015</xref>) and circadian TRPV4 modulation via β1 integrins (<xref ref-type="bibr" rid="bib60">Matthews et al., 2010</xref>), caveolin-1 (<xref ref-type="bibr" rid="bib49">Lakk et al., 2021</xref>), and cytoskeletal proteins (actin, actin adaptor proteins, microtubules) (<xref ref-type="bibr" rid="bib30">Goswami et al., 2010</xref>).</p><p>In conclusion, this study bridges biomechanical and biochemical paradigms of glaucomatous remodeling by extending the role of TGFβ2 beyond fibrosis to include TRPV4-dependent signaling and actomyosin contraction. We propose that TGFβ2-induced upregulation of TRPV4 expression shifts the normotensive setpoint maintained by steady-state TRPV4, Piezo1, and TREK-1 activity (<xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>; <xref ref-type="bibr" rid="bib113">Yarishkin et al., 2018a</xref>; <xref ref-type="bibr" rid="bib123">Zhu et al., 2021</xref>) to heighten the sensitivity of the conventional outflow pathway to mechanical cues. Mechanistically, this involves the hijacking of the contractile machinery and increased fibrotic remodeling, which in turn promote the pull of stress fibers on the ECM that had been stiffened by pressure- and cytokine-induced deposition of fibronectin, collagens, proteoglycans, and other ECM components (<xref ref-type="bibr" rid="bib55">Li et al., 2022b</xref>). The conserved TM TRPV4 expression (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>) and TM physiology in mice vs. humans (<xref ref-type="bibr" rid="bib12">Boussommier-Calleja et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Overby et al., 2014</xref>) suggest that the findings reported might be relevant in a clinical context. The absence of structural and functional visual phenotypes in <italic>Trpv4<sup>−/−</sup></italic> mice (<xref ref-type="bibr" rid="bib80">Redmon et al., 2024</xref>; <xref ref-type="bibr" rid="bib114">Yarishkin et al., 2018b</xref>; <xref ref-type="bibr" rid="bib40">Jo et al., 2016</xref>) additionally predicts that IOP lowering, suppression of fibrosis, and protection of retinal neurons from pressure by small-molecule TRPV4 antagonists can be implemented without compromising homeostatic IOP regulation (<xref ref-type="bibr" rid="bib88">Sharif, 2023</xref>).</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Animals</title><p>C57BL/6J mice were from JAX laboratories (Bar Harbor, ME), <italic>Trpv4</italic><sup>−/−</sup> (<italic>Trpv4<sup>tm1.1Ldtk</sup> Tg(KRT14-cre/ERT)20Efu/0</italic>; MGI:5544606) mice were a gift from Wolfgang Liedtke (Duke University) (<xref ref-type="bibr" rid="bib56">Liedtke and Friedman, 2003</xref>; <xref ref-type="bibr" rid="bib83">Ryskamp et al., 2011</xref>). The animals were maintained in a pathogen-free facility with a 12-hr light/dark cycle and ad libitum access to food and water, at a temperature of ~22–23°C. Mice were 2–6 months in age prior to LV injection; data from both male and female sexed animals were included in this study.</p></sec><sec id="s4-2"><title>Human TM culture</title><p>De-identified postmortem eyes from donors with no history of glaucoma (pTM cells) were procured from Utah Lions Eye Bank with written informed consent of the donor’s families. TM cells were isolated from juxtacanalicular and corneoscleral regions as previously described (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>). pTM cells were cultured in Trabecular Meshwork Cell Medium (TMCM; Sciencell Research Laboratories, Carlsbad, CA) in collagen-I-coated culture flasks and glass coverslips at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Fresh media was supplied every 2–3 days. Serum-free (SF) media was mixed as needed by excluding fetal bovine serum (FBS, Sciencell) from the TMCM. A list of all pTM strains used is available in <xref ref-type="table" rid="table1">Table 1</xref>; all cells were used between passages 2 and 4. Cell lines were chosen based on availability at the time of experiments.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Donor information for primary human trabecular meshwork (pTM) strains used in this study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Location</th><th align="left" valign="bottom">Donor age</th><th align="left" valign="bottom">Donor sex</th><th align="left" valign="bottom">Experiments used</th></tr></thead><tbody><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">55</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">PCR, Electrophysiology</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">76 (a)</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">PCR, WB, Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">76 (b)</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">PCR, Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">78</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">PCR, Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">64 (a)</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">PCR, WB, Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">64 (b)</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">PCR, Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">70 (a)</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">PCR, WB, Ca<sup>2+</sup> Img., Electrophysiology</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">70 (b)</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">PCR</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">53</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">26</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Ca<sup>2+</sup> Img., Electrophysiology</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">73</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">56</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">73</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Ca<sup>2+</sup> Img.</td></tr><tr><td align="left" valign="bottom">Utah</td><td align="char" char="." valign="bottom">80</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">WB</td></tr><tr><td align="left" valign="bottom">SUNY</td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Contractility</td></tr><tr><td align="left" valign="bottom">SUNY</td><td align="char" char="." valign="bottom">50</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">Contractility</td></tr><tr><td align="left" valign="bottom">SUNY</td><td align="char" char="." valign="bottom">56</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">Contractility</td></tr></tbody></table></table-wrap><p>TM cell lines were authenticated in accordance with consensus recommendations (<xref ref-type="bibr" rid="bib46">Keller et al., 2018</xref>) and validated as described (<xref ref-type="bibr" rid="bib84">Ryskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>) with DEX-induced upregulation of MYOC. There was no evidence of mycoplasma infection (i.e., DNA fragmentation/TUNEL, apoptosis, or reduced cell growth rate).</p><p>For contractility experiments, pTM cells were isolated from healthy donor corneal rims discarded after transplant surgery, as previously described (<xref ref-type="bibr" rid="bib55">Li et al., 2022b</xref>; <xref ref-type="bibr" rid="bib54">Li et al., 2022a</xref>; <xref ref-type="bibr" rid="bib7">Bagué et al., 2022</xref>), and cultured according to established protocols (<xref ref-type="bibr" rid="bib46">Keller et al., 2018</xref>; <xref ref-type="bibr" rid="bib94">Stamer et al., 1995</xref>). Three pTM cell strains isolated from healthy donors and validated with dexamethasone-induced myocilin expression were used for contractility experiments. pTM cells were cultured in low-glucose Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific, Waltham, MA) containing 10% FBS (R&amp;D Systems, Oakwood, GA) and 1% penicillin/streptomycin/glutamine (PSG; Gibco; Thermo Fisher) and maintained at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Fresh media was supplied every 2–3 days.</p><p>The experiments were conducted according to the tenets of the Declaration of Helsinki for the use of human tissue.</p></sec><sec id="s4-3"><title>Reagents</title><p>The TRPV4 antagonist HC-067047 (HC-06) was purchased from Millipore-Sigma (Burlington, MA) or Cayman Biotech (Ann Arbor, MI) and dissolved in DMSO at 20 mM. The TRPV4 agonist GSK1016790A (GSK101; Cayman Biotech) was dissolved in DMSO at 1 mM. Aliquots were diluted into working concentrations (10–25 nM, GSK101; 5–100 µM, HC-06). Recombinant human TGFβ2 protein (R&amp;D Systems) was reconstituted in sterile 4 mM HCl with 0.1% BSA at 20 µg/ml.</p></sec><sec id="s4-4"><title>Quantitative real-time PCR</title><p>Gene-specific primers were used to detect the expression of target genes, as described (<xref ref-type="bibr" rid="bib73">Phuong et al., 2017</xref>). Total RNA was isolated using the Arcturus PicoPure RNA isolation kit (Thermo Fisher Scientific). cDNA was generated from total RNA using qScript XLT cDNA Supermix (Quanta Bio, Beverly, MA). SYBR Green-based real-time PCR was performed with 2X GREEN Master Mix (Apex Bioresearch Products; Houston, TSX). GAPDH was used as an endogenous control to normalize fluorescence signals. Gene expression relative to GAPDH was measured using the comparative CT method (2<sup>−[ΔCT(gene) − ΔCT(GAPDH)]</sup>). All genes were assessed in four to eight individual samples taken from three to seven different pTM strains. The primer sequences, expected product length, and gene accession are provided in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Sequences, product size, and reference numbers for PCR primers used in this study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">Forward</th><th align="left" valign="bottom">Reverse</th><th align="left" valign="bottom">Product length (bp)</th><th align="left" valign="bottom">NCBI reference number</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>GAPDH</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTCCTGTTCGACAGTCAGCC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GACTCCGACCTTCACCTTCC</named-content></td><td align="char" char="." valign="bottom">89</td><td align="left" valign="bottom">NM_002046.5</td></tr><tr><td align="left" valign="bottom"><italic>SMAD2</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGGTTTTGAAGCCGTCTATCAGC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCAACCACTGTAGAGGTCCATTC</named-content></td><td align="char" char="." valign="bottom">149</td><td align="left" valign="bottom">NM_005901.6</td></tr><tr><td align="left" valign="bottom"><italic>SMAD3</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CAAGTGGCCGCGTGTAAAAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGTCCAGAACAGCCGAGTTG</named-content></td><td align="char" char="." valign="bottom">181</td><td align="left" valign="bottom">NM_005902.4</td></tr><tr><td align="left" valign="bottom"><italic>SMAD7</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTGCTCCCATCCTGTGTGTT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCTTGGGTTATGACGGACCA</named-content></td><td align="char" char="." valign="bottom">120</td><td align="left" valign="bottom">NM_005904.3</td></tr><tr><td align="left" valign="bottom"><italic>TGFΒR2</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AACCTCTAGGCACCCTCCTC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AACCTCTAGGCACCCTCCTC</named-content></td><td align="char" char="." valign="bottom">100</td><td align="left" valign="bottom">NM_001024847.3</td></tr><tr><td align="left" valign="bottom"><italic>FSP1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GCTTCTTCTTTCTTGGTTTGATCCT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AAGTCCACCTCGTTGTCCCT</named-content></td><td align="char" char="." valign="bottom">250</td><td align="left" valign="bottom">NM_002961.3</td></tr><tr><td align="left" valign="bottom"><italic>SNAIL1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGCTCCTTCGTCCTTCTCCTCTAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CTGGAGATCCTTGGCCTCAGAGAG</named-content></td><td align="char" char="." valign="bottom">124</td><td align="left" valign="bottom">NM_005985.4</td></tr><tr><td align="left" valign="bottom"><italic>CCN2</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCCCAGACACTGGTTTGAAG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCCACTGCTCCTAAAGCCAC</named-content></td><td align="char" char="." valign="bottom">100</td><td align="left" valign="bottom">NM_001901.3</td></tr><tr><td align="left" valign="bottom"><italic>YAP1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ACAGGGAAGTGACTTTGTACA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GCACTGAATATTGCACCCAC</named-content></td><td align="char" char="." valign="bottom">183</td><td align="left" valign="bottom">NM_001130145.</td></tr><tr><td align="left" valign="bottom"><italic>FN1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTGAAAGACCAGCAGAGGCA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GTGTAGGGGTCAAAGCACGA</named-content></td><td align="char" char="." valign="bottom">110</td><td align="left" valign="bottom">M10905.1</td></tr><tr><td align="left" valign="bottom"><italic>SMA (ACTA2)</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GTCACCCACAATGTCCCCAT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGAATAGCCACGCTCAGTCA</named-content></td><td align="char" char="." valign="bottom">123</td><td align="left" valign="bottom">NM_001141945.2</td></tr><tr><td align="left" valign="bottom"><italic>MYOC</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCACGTGGAGAATCGACACA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCAGTGGCCTAGGCAGTAT</named-content></td><td align="char" char="." valign="bottom">118</td><td align="left" valign="bottom">NM_000261.1</td></tr><tr><td align="left" valign="bottom"><italic>TRPV4</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCCATTCTTGCTGACCCAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGGGCTGTCTGACCTCGATA</named-content></td><td align="char" char="." valign="bottom">217</td><td align="left" valign="bottom">NM_021625.4</td></tr><tr><td align="left" valign="bottom"><italic>PIEZO1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGCCAACTTCCTCACCAAGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGGTATTTCTTCTCTGTCTC</named-content></td><td align="char" char="." valign="bottom">106</td><td align="left" valign="bottom">NM_001142864.3</td></tr><tr><td align="left" valign="bottom"><italic>TREK1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AGGGATTTCTACTTGGCGGC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CAAGCACTGTGGGTTTCGTG</named-content></td><td align="char" char="." valign="bottom">99</td><td align="left" valign="bottom">NM_001017424.3</td></tr><tr><td align="left" valign="bottom"><italic>TRPC1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TGCGTAGATGTGCTTGGGAG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CGTTCCATTAGTTTCTGACAACCG</named-content></td><td align="char" char="." valign="bottom">107</td><td align="left" valign="bottom">X89066.1</td></tr></tbody></table></table-wrap></sec><sec id="s4-5"><title>Western blot</title><p>Three SF- or TGFβ2-treated samples were pelleted and pooled together from three different pTM samples within the same condition. To separate membrane proteins from heavier cellular debris, the pooled cell pellets were homogenized in a hypotonic lysis buffer (20 mM Tris-HCl, 3 mM MgCl<sub>2</sub>, 10 mM NaCl, 10 mM PMSF, 0.5 mM DTT, 20 mM NaF, 2 mM NaV, 0.5 µg/ml leupeptin) before centrifuging at 300 × <italic>g</italic> for 5 min (4°C). The resulting supernatant was removed and centrifuged again at &gt;12,500 rpm for 30 min to pellet membrane proteins, which were then resuspended in RIPA Buffer (Santa Cruz). Proteins were separated on a 10% SDS–PAGE gel and transferred to polyvinylidene difluoride membranes (Bio-Rad). Membranes were blocked with 5% skim milk/2% BSA in TBST and incubated at 4°C overnight with a primary antibody against TRPV4 (1:250, Alomone Labs #ACC-034; Jerusalem, Israel) or rabbit antibody against β-tubulin (1:2000, Abcam #EPR1330; Waltham, MA). Appropriate secondary antibodies conjugated to HRP were used to visualize protein expression on an iBright CL750 imaging system (Thermo Fisher Scientific). β-Tubulin expression was used to standardize protein levels between samples.</p></sec><sec id="s4-6"><title>Calcium Imaging</title><p>Primary human TM cells were seeded onto collagen-I-coated coverslips and cultured in TMCM media (ScienCell) as described (<xref ref-type="bibr" rid="bib115">Yarishkin et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Lakk and Križaj, 2021</xref>). The cells were serum starved for 24 hr followed by SF TMCM with or without TGFβ2 (1 or 5 ng/ml) for 24 hr or 5 days. The cells were loaded with 10 µM of the ratiometric indicator Fura-2 AM K<sub>d</sub> at RT = 225 nM (Invitrogen/Thermo Fisher) for 30–60 min. Coverslips were placed in an RC-26G chamber platform (Warner Instrument Corp, Hamden, CT) and perfused with external saline (pH 7.4) (in mM): 80 NaCl, 4.7 KCl, 1.2 MgCl<sub>2</sub>, 10 <sc>D</sc>-glucose, 19.1 HEPES sodium salt, 2 CaCl<sub>2</sub>, and osmolality adjusted to 300 mOsm using <sc>D</sc>-mannitol. External solutions were delivered via a manually controlled gravity-fed eight-line manifold system, with perfusion speed kept constant to minimize changes in shear. Epifluorescence imaging was performed using an inverted Nikon Ti microscope with a 40× 1.3 N.A. oil objective and Nikon Elements AR software. 340 and 380 nm excitation were delivered by a high-intensity 150 W Xenon arc lamp (Lambda DG-4; Sutter Instruments), high pass-filtered at 510 nm and detected with a 12-bit Delta Evolve camera (Teledyne Photometrics; Tucson, CA). GSK101 10 nM evoked Δ[Ca<sup>2+</sup>]<sub>i</sub> was assessed as ∆<italic>R</italic>/<italic>R</italic> (dividing the difference between the peak GSK-evoked <italic>F</italic><sub>340</sub>/<italic>F</italic><sub>380</sub> signal during stimulation and baseline <italic>F</italic><sub>340</sub>/<italic>F</italic><sub>380</sub> signal by the baseline <italic>F</italic><sub>340</sub>/<italic>F</italic><sub>380</sub> signal). Every data point represents a separate experimental day and pTM cell strain, each with three to five control and three to five TGFβ2-treated slides tested on the same day. TGFβ2 data points represent the average GSK101 evoked ∆<italic>R</italic>/<italic>R</italic> across all TGFβ2 cells as a % of the average ∆<italic>R</italic>/<italic>R</italic> of control cells from the same cell strain on the same day.</p></sec><sec id="s4-7"><title>Collagen hydrogel contraction assay</title><p>Rat tail collagen type I (Thermo Fisher Scientific) was prepared at a concentration of 1.5 mg/ml according to the manufacturer’s instructions. Five hundred microliters of the hydrogel solution were pipetted into 24-well culture plates. Upon complete collagen polymerization, pTM cells were seeded at 1.5 × 10<sup>5</sup> cells/well atop the hydrogels and cultured in DMEM + 10% FBS + 1% PSG for 48 hr to facilitate even cell spreading. Next, constructs were cultured in SF DMEM + 1% PSG supplemented with: (i) control (vehicle: 0.008 mM HCl + 0.0004% BSA; 0.025% DMSO), (ii) TGFβ2 (5 ng/ml; R&amp;D Systems), or (iii and iv) TGFβ2 + HC067047 (5 µM in DMSO) for 36 hr before carefully releasing the hydrogels from the walls using a sterile 10 µl pipette tip to facilitate contraction. The next morning, fresh SF DMEM + 1% PSG supplemented with 0.0025% DMSO = vehicle was added to groups i–iii; group iv received SF DMEM + 1% PSG supplemented with GSK1016790A (25 nM in DMSO). Plates were longitudinally imaged at 600 dpi resolution with a CanoScan LiDE 300 flatbed scanner at 0, 15, 30, 60, and 120 min. Hydrogel construct size was quantified using FIJI software (National Institutes of Health) (<xref ref-type="bibr" rid="bib87">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-8"><title>Electrophysiology</title><p>Borosilicate patch-clamp pipettes (WPI) were pulled using a P-2000 horizontal micropipette puller (Sutter Instruments), with a resistance of 6–8 MΩ. The internal solution contained (mM): 125 K-gluconate, 10 KCl, 1.5 MgCl<sub>2</sub>, 10 HEPES, 10 EGTA, pH 7.4. Patch clamp data were acquired with a Multiclamp 700B amplifier, pClamp 10.6 software, and Digidata 1440A interface (Molecular Devices; San Jose CA), sampled at 5 kHz and analyzed with Clampfit 10.7. Current–voltage relationships were assessed using <italic>V</italic><sub>m</sub> steps from –100 to +100 mV against a holding potential of –30 mV. Current density was measured as the average current during GSK101 exposure subtracted by the average current from the same cell during baseline perfusion.</p></sec><sec id="s4-9"><title>IOP measurements</title><p>A TonoLab rebound tonometer (Colonial Medical Supply; Franconia NH) was used to measure IOP of awake mice between 12 and 2 PM. IOP was determined from the mean of 10–20 tonometer readings. Nocturnal measurements were conducted between 9 and 10 PM in awake animals or under 2.5% isoflurane delivered by a Somnosuite isoflurane vaporizer (Kent Scientific; Torrington, CT). After animals recovered from intracameral HC-06/PBS injections, IOP was measured daily. IOP was measured every day for 4–5 consecutive days to confirm a stable return to baseline. IOP data for individual cohorts were binned into weeks of experimental time to group values for analysis.</p></sec><sec id="s4-10"><title>Lentiviral transduction</title><p>Lentiviral stock for TGFβ2 (C226,228S) was purchased from VectorBuilder Inc (Chicago, IL) (VB170816-1094fnw, pLV[Exp]-CMV&gt; {hTGFB2[NM_003238.3](C226,228S)}) (<xref ref-type="bibr" rid="bib71">Patil et al., 2022</xref>). Scrambled control lentivirus was purchased from SignaGen Laboratories (Frederick, MD) (LM-CMV-Null-Puro). Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine (90 mg/10 mg/kg body weight), followed by eyedrops containing 0.5% proparacaine hydrochloride and 1% tropicamide ophthalmic solution to numb the eyes and dilate the pupils. Anesthetized mice were secured to allow stereotaxic injection of lentivirus. Intravitreal injections were conducted by creating a guide hole with a 30-gauge needle 1–2 mm equatorial of the cornea–scleral border, followed by insertion of a 12° beveled 33-gauge Hamilton syringe, secured to a stereotaxic rig (World Precision Instruments; Sarasota, FL) used to insert the needle 2–3 mm into the eye. Each eye was injected with a 2-µl bolus of lentivirus diluted to 1 × 10<sup>6</sup> TU/µl over the course of 1 min, before the needle was quickly drawn and the pilot hole treated with erythromycin ophthalmic ointment USP (Bausch &amp; Lomb; Laval, Canada). The efficiency of LV-TGFβ2 OHT induction in WT animals was close to 100%. No differences in observable health post-injection were detected between wild-type and <italic>Trpv4</italic><sup>−/−</sup> animals or LV-Ctrl and LV-TGFβ2 injected animals.</p></sec><sec id="s4-11"><title>Intracameral microinjections</title><p>Mice were anesthetized and treated with eyedrops as above, before being placed on an isothermal heating pad. HC-06 (100 µM) or PBS with DMSO (0.5%) as a vehicle were injected into the anterior chamber using a blunt tip Hamilton syringe through a guide hole made using a 30-gauge needle. At the end of each injection, a small air bubble was introduced to seal the cornea and minimize fluid outflow. 0.5% erythromycin ophthalmic ointment USP (Bausch &amp; Lomb) was applied to the eye after the procedure. Intracameral injections were not associated with observable inflammation, corneal opacity, or behavioral changes. For the nocturnal IOP experiments in <xref ref-type="fig" rid="fig6">Figure 6</xref>, both eyes of two animals were injected with PBS while two were injected with HC-06. When OHT was stably reestablished a week post-injection, the treatment groups were switched, and experiments repeated, resulting in four eyes/treatment group for <xref ref-type="fig" rid="fig6">Figure 6E, F</xref>.</p></sec><sec id="s4-12"><title>Statistical analysis</title><p>GraphPad Prism 9 was used for statistical analysis. Means are plotted ± SEM unless otherwise noted. One-sample <italic>t</italic>-tests were used to determine whether TGFβ2-treated groups were significantly different than untreated control groups, while one- or two-way ANOVA along with Tukey or Bonferroni’s multiple comparisons test were used to compare multiple groups.</p></sec><sec id="s4-13"><title>Study approval</title><p>The animal experimental protocols were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee at the University of Utah (protocol 25-00001905).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Co-founder of TMClear and co-inventor of patents (US 2015/0133411, US20230026696) related to the development of cornea permeant TRPV4 channel antagonists; the patents were licensed to TMClear by the University of Utah</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con8"><p>Conceptualization</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal handling, anesthetic procedures, and experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committees at the University of Utah (protocol 25-00001905).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-104894-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Individual datapoints for in vivo figures, and unedited/uncropped annotated western blot images are included in the supplementary data files for this manuscript. Source data has been provided for Figures 5 and 6. Further information about the data presented in this manuscript is available from the corresponding authors upon reasonable request.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Paloma Liton (Duke University) for the generous gift of LV-TGFβ2<sup>C226,228S</sup> lentivirus stock used for the pilot stages of this experiment, and Dr. Gulab Zode for the availability of the LV-TGFβ2<sup>C226,228S</sup> construct on Vectorbuilder. We additionally thank Dr. Wolfgang Liedtke (Duke University and Regeneron) for <italic>Trpv4<sup>−/−</sup></italic> mice. The study was supported by the National Institutes of Health (T32EY024234 to CNR and DK, R01EY022076, R0EY1031817, P30EY014800 to DK, R01EY034096, R21EY036189 to SH, R01EY022359, R01EY005722 to WDS), Crandall Glaucoma Initiative, Stauss-Rankin Foundation, and Unrestricted Grants from Research to Prevent Blindness to Ophthalmology Departments Duke University, SUNY Upstate Medical University, and the University of Utah. Schematics were made with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">Biorender.com</ext-link>.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abad</surname><given-names>E</given-names></name><name><surname>Lorente</surname><given-names>G</given-names></name><name><surname>Gavara</surname><given-names>N</given-names></name><name><surname>Morales</surname><given-names>M</given-names></name><name><surname>Gual</surname><given-names>A</given-names></name><name><surname>Gasull</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Activation of store-operated Ca <sup>2+</sup> channels in trabecular meshwork cells</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>49</volume><elocation-id>677</elocation-id><pub-id pub-id-type="doi">10.1167/iovs.07-1080</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acott</surname><given-names>TS</given-names></name><name><surname>Vranka</surname><given-names>JA</given-names></name><name><surname>Keller</surname><given-names>KE</given-names></name><name><surname>Raghunathan</surname><given-names>VK</given-names></name><name><surname>Kelley</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Normal and glaucomatous outflow regulation</article-title><source>Progress in Retinal and Eye Research</source><volume>82</volume><elocation-id>100897</elocation-id><pub-id pub-id-type="doi">10.1016/j.preteyeres.2020.100897</pub-id><pub-id pub-id-type="pmid">32795516</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adapala</surname><given-names>RK</given-names></name><name><surname>Thoppil</surname><given-names>RJ</given-names></name><name><surname>Luther</surname><given-names>DJ</given-names></name><name><surname>Paruchuri</surname><given-names>S</given-names></name><name><surname>Meszaros</surname><given-names>JG</given-names></name><name><surname>Chilian</surname><given-names>WM</given-names></name><name><surname>Thodeti</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>54</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2012.10.016</pub-id><pub-id pub-id-type="pmid">23142541</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>P</given-names></name><name><surname>Daher</surname><given-names>AM</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Aqueous humor TGF-β2 levels in patients with open-angle glaucoma: a meta-analysis</article-title><source>Molecular Vision</source><volume>21</volume><fpage>612</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">26019480</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessandri-Haber</surname><given-names>N</given-names></name><name><surname>Dina</surname><given-names>OA</given-names></name><name><surname>Joseph</surname><given-names>EK</given-names></name><name><surname>Reichling</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators</article-title><source>The Journal of Neuroscience</source><volume>26</volume><fpage>3864</fpage><lpage>3874</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5385-05.2006</pub-id><pub-id pub-id-type="pmid">16597741</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almasieh</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>AM</given-names></name><name><surname>Morquette</surname><given-names>B</given-names></name><name><surname>Cueva Vargas</surname><given-names>JL</given-names></name><name><surname>Di Polo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The molecular basis of retinal ganglion cell death in glaucoma</article-title><source>Progress in Retinal and Eye Research</source><volume>31</volume><fpage>152</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2011.11.002</pub-id><pub-id pub-id-type="pmid">22155051</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagué</surname><given-names>T</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Ghosh</surname><given-names>R</given-names></name><name><surname>Yoo</surname><given-names>H</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>deLong</surname><given-names>MA</given-names></name><name><surname>Kopczynski</surname><given-names>CC</given-names></name><name><surname>Herberg</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effects of netarsudil-family rho kinase inhibitors on human trabecular meshwork cell contractility and actin remodeling using a bioengineered ECM hydrogel</article-title><source>Frontiers in Ophthalmology</source><volume>2</volume><elocation-id>948397</elocation-id><pub-id pub-id-type="doi">10.3389/fopht.2022.948397</pub-id><pub-id pub-id-type="pmid">38983571</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudouin</surname><given-names>C</given-names></name><name><surname>Kolko</surname><given-names>M</given-names></name><name><surname>Melik-Parsadaniantz</surname><given-names>S</given-names></name><name><surname>Messmer</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inflammation in glaucoma: from the back to the front of the eye, and beyond</article-title><source>Progress in Retinal and Eye Research</source><volume>83</volume><elocation-id>100916</elocation-id><pub-id pub-id-type="doi">10.1016/j.preteyeres.2020.100916</pub-id><pub-id pub-id-type="pmid">33075485</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>JM</given-names></name><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>De Ieso</surname><given-names>ML</given-names></name><name><surname>Rudzitis</surname><given-names>CN</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Tseng</surname><given-names>YT</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>TRPV4 and chloride channels mediate volume sensing in trabecular meshwork cells</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>327</volume><fpage>C403</fpage><lpage>C414</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00295.2024</pub-id><pub-id pub-id-type="pmid">38881423</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrás</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Gene expression in the trabecular meshwork and the influence of intraocular pressure</article-title><source>Progress in Retinal and Eye Research</source><volume>22</volume><fpage>435</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/s1350-9462(03)00018-1</pub-id><pub-id pub-id-type="pmid">12742391</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrás</surname><given-names>T</given-names></name><name><surname>Buie</surname><given-names>LK</given-names></name><name><surname>Spiga</surname><given-names>MG</given-names></name><name><surname>Carabana</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prevention of nocturnal elevation of intraocular pressure by gene transfer of dominant-negative RhoA in rats</article-title><source>JAMA Ophthalmology</source><volume>133</volume><fpage>182</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2014.4747</pub-id><pub-id pub-id-type="pmid">25412195</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boussommier-Calleja</surname><given-names>A</given-names></name><name><surname>Bertrand</surname><given-names>J</given-names></name><name><surname>Woodward</surname><given-names>DF</given-names></name><name><surname>Ethier</surname><given-names>CR</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name><name><surname>Overby</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>53</volume><fpage>5838</fpage><lpage>5845</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-9923</pub-id><pub-id pub-id-type="pmid">22807298</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brubaker</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>The effect of intraocular pressure on conventional outflow resistance in the enucleated human eye</article-title><source>Investigative Ophthalmology</source><volume>14</volume><fpage>286</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">1123284</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera-Benítez</surname><given-names>NE</given-names></name><name><surname>Parotto</surname><given-names>M</given-names></name><name><surname>Post</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Spieth</surname><given-names>PM</given-names></name><name><surname>Cheng</surname><given-names>W-E</given-names></name><name><surname>Valladares</surname><given-names>F</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mechanical stress induces lung fibrosis by epithelial-mesenchymal transition</article-title><source>Critical Care Medicine</source><volume>40</volume><fpage>510</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31822f09d7</pub-id><pub-id pub-id-type="pmid">21926573</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaghan</surname><given-names>B</given-names></name><name><surname>Lester</surname><given-names>K</given-names></name><name><surname>Lane</surname><given-names>B</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Goljanek-Whysall</surname><given-names>K</given-names></name><name><surname>Simpson</surname><given-names>DA</given-names></name><name><surname>Sheridan</surname><given-names>C</given-names></name><name><surname>Willoughby</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genome-wide transcriptome profiling of human trabecular meshwork cells treated with TGF-β2</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>9564</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-13573-8</pub-id><pub-id pub-id-type="pmid">35689009</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreon</surname><given-names>T</given-names></name><name><surname>van der Merwe</surname><given-names>E</given-names></name><name><surname>Fellman</surname><given-names>RL</given-names></name><name><surname>Johnstone</surname><given-names>M</given-names></name><name><surname>Bhattacharya</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Aqueous outflow - A continuum from trabecular meshwork to episcleral veins</article-title><source>Progress in Retinal and Eye Research</source><volume>57</volume><fpage>108</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2016.12.004</pub-id><pub-id pub-id-type="pmid">28028002</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaigne</surname><given-names>S</given-names></name><name><surname>Barbeau</surname><given-names>S</given-names></name><name><surname>Ducret</surname><given-names>T</given-names></name><name><surname>Guinamard</surname><given-names>R</given-names></name><name><surname>Benoist</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Pathophysiological roles of the TRPV4 Channel in the Heart</article-title><source>Cells</source><volume>12</volume><elocation-id>1654</elocation-id><pub-id pub-id-type="doi">10.3390/cells12121654</pub-id><pub-id pub-id-type="pmid">37371124</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Daneva</surname><given-names>Z</given-names></name><name><surname>Kuppusamy</surname><given-names>M</given-names></name><name><surname>Ottolini</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>TM</given-names></name><name><surname>Klimentova</surname><given-names>E</given-names></name><name><surname>Shah</surname><given-names>SA</given-names></name><name><surname>Sokolowski</surname><given-names>JD</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Sonkusare</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Novel smooth muscle Ca<sup>2+</sup>-signaling nanodomains in blood pressure regulation</article-title><source>Circulation</source><volume>146</volume><fpage>548</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.058607</pub-id><pub-id pub-id-type="pmid">35758040</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coker</surname><given-names>RK</given-names></name><name><surname>Laurent</surname><given-names>GJ</given-names></name><name><surname>Shahzeidi</surname><given-names>S</given-names></name><name><surname>Lympany</surname><given-names>PA</given-names></name><name><surname>du Bois</surname><given-names>RM</given-names></name><name><surname>Jeffery</surname><given-names>PK</given-names></name><name><surname>McAnulty</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis</article-title><source>The American Journal of Pathology</source><volume>150</volume><fpage>981</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/S0923-1811(99)00008-0</pub-id><pub-id pub-id-type="pmid">9060836</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y-Y</given-names></name><name><surname>Li</surname><given-names>M-Y</given-names></name><name><surname>Li</surname><given-names>Y-T</given-names></name><name><surname>Ning</surname><given-names>J-Y</given-names></name><name><surname>Gou</surname><given-names>X-C</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y-Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Expression and functional characterization of transient receptor potential vanilloid 4 in the dorsal root ganglion and spinal cord of diabetic rats with mechanical allodynia</article-title><source>Brain Research Bulletin</source><volume>162</volume><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2020.05.010</pub-id><pub-id pub-id-type="pmid">32479780</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daneva</surname><given-names>Z</given-names></name><name><surname>Marziano</surname><given-names>C</given-names></name><name><surname>Ottolini</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Baker</surname><given-names>TM</given-names></name><name><surname>Kuppusamy</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Ta</surname><given-names>HQ</given-names></name><name><surname>Reagan</surname><given-names>CE</given-names></name><name><surname>Mihalek</surname><given-names>AD</given-names></name><name><surname>Kasetti</surname><given-names>RB</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Isakson</surname><given-names>BE</given-names></name><name><surname>Minshall</surname><given-names>RD</given-names></name><name><surname>Zode</surname><given-names>GS</given-names></name><name><surname>Goncharova</surname><given-names>EA</given-names></name><name><surname>Laubach</surname><given-names>VE</given-names></name><name><surname>Sonkusare</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Caveolar peroxynitrite formation impairs endothelial TRPV4 channels and elevates pulmonary arterial pressure in pulmonary hypertension</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2023130118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2023130118</pub-id><pub-id pub-id-type="pmid">33879616</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Kater</surname><given-names>AW</given-names></name><name><surname>Shahsafaei</surname><given-names>A</given-names></name><name><surname>Epstein</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Localization of smooth muscle and nonmuscle actin isoforms in the human aqueous outflow pathway</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>33</volume><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">1740375</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ethier</surname><given-names>CR</given-names></name><name><surname>Read</surname><given-names>AT</given-names></name><name><surname>Chan</surname><given-names>DWH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Effects of latrunculin-b on outflow facility and trabecular meshwork structure in human eyes</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>47</volume><elocation-id>1991</elocation-id><pub-id pub-id-type="doi">10.1167/iovs.05-0327</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feger</surname><given-names>M</given-names></name><name><surname>Hase</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Hirche</surname><given-names>F</given-names></name><name><surname>Glosse</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>Föller</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The production of fibroblast growth factor 23 is controlled by TGF-β2</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>4982</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-05226-y</pub-id><pub-id pub-id-type="pmid">28694529</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleenor</surname><given-names>DL</given-names></name><name><surname>Shepard</surname><given-names>AR</given-names></name><name><surname>Hellberg</surname><given-names>PE</given-names></name><name><surname>Jacobson</surname><given-names>N</given-names></name><name><surname>Pang</surname><given-names>I-H</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TGFβ2-induced changes in human trabecular meshwork: implications for intraocular pressure</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>47</volume><elocation-id>226</elocation-id><pub-id pub-id-type="doi">10.1167/iovs.05-1060</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchshofer</surname><given-names>R</given-names></name><name><surname>Birke</surname><given-names>M</given-names></name><name><surname>Welge-Lussen</surname><given-names>U</given-names></name><name><surname>Kook</surname><given-names>D</given-names></name><name><surname>Lu¨tjen-Drecoll</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Transforming growth factor-β2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>46</volume><elocation-id>568</elocation-id><pub-id pub-id-type="doi">10.1167/iovs.04-0649</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchshofer</surname><given-names>R</given-names></name><name><surname>Stephan</surname><given-names>DA</given-names></name><name><surname>Russell</surname><given-names>P</given-names></name><name><surname>Tamm</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Gene expression profiling of TGFβ2- and/or BMP7-treated trabecular meshwork cells: Identification of Smad7 as a critical inhibitor of TGF-β2 signaling</article-title><source>Experimental Eye Research</source><volume>88</volume><fpage>1020</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2009.01.002</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchshofer</surname><given-names>R</given-names></name><name><surname>Tamm</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The role of TGF-β in the pathogenesis of primary open-angle glaucoma</article-title><source>Cell and Tissue Research</source><volume>347</volume><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s00441-011-1274-7</pub-id><pub-id pub-id-type="pmid">22101332</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>MO</given-names></name><name><surname>Beiser</surname><given-names>JA</given-names></name><name><surname>Brandt</surname><given-names>JD</given-names></name><name><surname>Heuer</surname><given-names>DK</given-names></name><name><surname>Higginbotham</surname><given-names>EJ</given-names></name><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Keltner</surname><given-names>JL</given-names></name><name><surname>Miller</surname><given-names>JP</given-names></name><name><surname>Wilson</surname><given-names>MR</given-names></name><name><surname>Kass</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma</article-title><source>Archives of Ophthalmology</source><volume>120</volume><fpage>714</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1001/archopht.120.6.714</pub-id><pub-id pub-id-type="pmid">12049575</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>C</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Heppenstall</surname><given-names>PA</given-names></name><name><surname>Hucho</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Importance of non-selective cation channel TRPV4 interaction with cytoskeleton and their reciprocal regulations in cultured cells</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e11654</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0011654</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottanka</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Eichhorn</surname><given-names>M</given-names></name><name><surname>Lütjen-Drecoll</surname><given-names>E</given-names></name><name><surname>Ethier</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Effects of TGF- 2 in perfused human eyes</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>45</volume><fpage>153</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1167/iovs.03-0796</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grove</surname><given-names>LM</given-names></name><name><surname>Mohan</surname><given-names>ML</given-names></name><name><surname>Abraham</surname><given-names>S</given-names></name><name><surname>Scheraga</surname><given-names>RG</given-names></name><name><surname>Southern</surname><given-names>BD</given-names></name><name><surname>Crish</surname><given-names>JF</given-names></name><name><surname>Naga Prasad</surname><given-names>SV</given-names></name><name><surname>Olman</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Translocation of TRPV4-PI3Kγ complexes to the plasma membrane drives myofibroblast transdifferentiation</article-title><source>Science Signaling</source><volume>12</volume><elocation-id>eaau1533</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aau1533</pub-id><pub-id pub-id-type="pmid">31719171</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Güler</surname><given-names>AD</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>I</given-names></name><name><surname>Tominaga</surname><given-names>M</given-names></name><name><surname>Caterina</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Heat-evoked activation of the ion channel, TRPV4</article-title><source>The Journal of Neuroscience</source><volume>22</volume><fpage>6408</fpage><lpage>6414</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-15-06408.2002</pub-id><pub-id pub-id-type="pmid">12151520</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijl</surname><given-names>A</given-names></name><name><surname>Leske</surname><given-names>MC</given-names></name><name><surname>Bengtsson</surname><given-names>B</given-names></name><name><surname>Hyman</surname><given-names>L</given-names></name><name><surname>Bengtsson</surname><given-names>B</given-names></name><name><surname>Hussein</surname><given-names>M</given-names></name><collab>Early Manifest Glaucoma Trial Group</collab></person-group><year iso-8601-date="2002">2002</year><article-title>Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial</article-title><source>Archives of Ophthalmology</source><volume>120</volume><fpage>1268</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1001/archopht.120.10.1268</pub-id><pub-id pub-id-type="pmid">12365904</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honjo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes</article-title><source>Archives of Ophthalmology</source><volume>119</volume><fpage>1171</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1001/archopht.119.8.1171</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikegami</surname><given-names>K</given-names></name><name><surname>Masubuchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Suppression of trabecular meshwork phagocytosis by norepinephrine is associated with nocturnal increase in intraocular pressure in mice</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>339</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03295-y</pub-id><pub-id pub-id-type="pmid">35396348</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikegami</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Circadian rhythm of intraocular pressure</article-title><source>The Journal of Physiological Sciences: JPS</source><volume>74</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1097/IJG.0000000000001402</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue-Mochita</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>T</given-names></name><name><surname>Kameda</surname><given-names>T</given-names></name><name><surname>Awai-Kasaoka</surname><given-names>N</given-names></name><name><surname>Ohtsu</surname><given-names>N</given-names></name><name><surname>Kimoto</surname><given-names>K</given-names></name><name><surname>Tanihara</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>P38 MAP kinase inhibitor suppresses transforming growth factor-β2-induced type 1 collagen production in trabecular meshwork cells</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0120774</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0120774</pub-id><pub-id pub-id-type="pmid">25799097</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Role of mechanically-sensitive cation channels Piezo1 and TRPV4 in trabecular meshwork cell mechanotransduction</article-title><source>Human Cell</source><volume>37</volume><fpage>394</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1007/s13577-024-01035-4</pub-id><pub-id pub-id-type="pmid">38316716</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>AO</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Frye</surname><given-names>AM</given-names></name><name><surname>Phuong</surname><given-names>TTT</given-names></name><name><surname>Redmon</surname><given-names>SN</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Berkowitz</surname><given-names>BA</given-names></name><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Differential volume regulation and calcium signaling in two ciliary body cell types is subserved by TRPV4 channels</article-title><source>PNAS</source><volume>113</volume><fpage>3885</fpage><lpage>3890</lpage><pub-id pub-id-type="doi">10.1073/pnas.1515895113</pub-id><pub-id pub-id-type="pmid">27006502</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnstone</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Intraocular pressure regulation: findings of pulse-dependent trabecular meshwork motion lead to unifying concepts of intraocular pressure homeostasis</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>30</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1089/jop.2013.0224</pub-id><pub-id pub-id-type="pmid">24359130</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JL</given-names></name><name><surname>Peana</surname><given-names>D</given-names></name><name><surname>Veteto</surname><given-names>AB</given-names></name><name><surname>Lambert</surname><given-names>MD</given-names></name><name><surname>Nourian</surname><given-names>Z</given-names></name><name><surname>Karasseva</surname><given-names>NG</given-names></name><name><surname>Hill</surname><given-names>MA</given-names></name><name><surname>Lindman</surname><given-names>BR</given-names></name><name><surname>Baines</surname><given-names>CP</given-names></name><name><surname>Krenz</surname><given-names>M</given-names></name><name><surname>Domeier</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TRPV4 increases cardiomyocyte calcium cycling and contractility yet contributes to damage in the aged heart following hypoosmotic stress</article-title><source>Cardiovascular Research</source><volume>115</volume><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvy156</pub-id><pub-id pub-id-type="pmid">29931225</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>MH</given-names></name><name><surname>Oh</surname><given-names>D-J</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Rhee</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of SPARC by transforming growth factor β2 in human trabecular meshwork</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>54</volume><fpage>2523</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-11474</pub-id><pub-id pub-id-type="pmid">23513064</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>A</given-names></name><name><surname>Razaghi</surname><given-names>R</given-names></name><name><surname>Rahmati</surname><given-names>SM</given-names></name><name><surname>Downs</surname><given-names>JC</given-names></name><name><surname>Acott</surname><given-names>TS</given-names></name><name><surname>Kelley</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>RK</given-names></name><name><surname>Johnstone</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The effect of intraocular pressure load boundary on the biomechanics of the human conventional aqueous outflow pathway</article-title><source>Bioengineering</source><volume>9</volume><elocation-id>672</elocation-id><pub-id pub-id-type="doi">10.3390/bioengineering9110672</pub-id><pub-id pub-id-type="pmid">36354583</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katari</surname><given-names>V</given-names></name><name><surname>Bhavnani</surname><given-names>N</given-names></name><name><surname>Paruchuri</surname><given-names>S</given-names></name><name><surname>Thodeti</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TRPV4 regulates matrix stiffness‐dependent activation of YAP/VEGFR2 signaling via Rho/Rho kinase/LATS1/2 pathway</article-title><source>The FASEB Journal</source><volume>35</volume><elocation-id>e3643</elocation-id><pub-id pub-id-type="doi">10.1096/fasebj.2021.35.S1.03643</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>KE</given-names></name><name><surname>Bhattacharya</surname><given-names>SK</given-names></name><name><surname>Borrás</surname><given-names>T</given-names></name><name><surname>Brunner</surname><given-names>TM</given-names></name><name><surname>Chansangpetch</surname><given-names>S</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name><name><surname>Dismuke</surname><given-names>WM</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Elliott</surname><given-names>MH</given-names></name><name><surname>Ethier</surname><given-names>CR</given-names></name><name><surname>Faralli</surname><given-names>JA</given-names></name><name><surname>Freddo</surname><given-names>TF</given-names></name><name><surname>Fuchshofer</surname><given-names>R</given-names></name><name><surname>Giovingo</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>Gonzalez</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Johnstone</surname><given-names>MA</given-names></name><name><surname>Kaufman</surname><given-names>PL</given-names></name><name><surname>Kelley</surname><given-names>MJ</given-names></name><name><surname>Knepper</surname><given-names>PA</given-names></name><name><surname>Kopczynski</surname><given-names>CC</given-names></name><name><surname>Kuchtey</surname><given-names>JG</given-names></name><name><surname>Kuchtey</surname><given-names>RW</given-names></name><name><surname>Kuehn</surname><given-names>MH</given-names></name><name><surname>Lieberman</surname><given-names>RL</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Liton</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lütjen-Drecoll</surname><given-names>E</given-names></name><name><surname>Mao</surname><given-names>W</given-names></name><name><surname>Masis-Solano</surname><given-names>M</given-names></name><name><surname>McDonnell</surname><given-names>F</given-names></name><name><surname>McDowell</surname><given-names>CM</given-names></name><name><surname>Overby</surname><given-names>DR</given-names></name><name><surname>Pattabiraman</surname><given-names>PP</given-names></name><name><surname>Raghunathan</surname><given-names>VK</given-names></name><name><surname>Rao</surname><given-names>PV</given-names></name><name><surname>Rhee</surname><given-names>DJ</given-names></name><name><surname>Chowdhury</surname><given-names>UR</given-names></name><name><surname>Russell</surname><given-names>P</given-names></name><name><surname>Samples</surname><given-names>JR</given-names></name><name><surname>Schwartz</surname><given-names>D</given-names></name><name><surname>Stubbs</surname><given-names>EB</given-names></name><name><surname>Tamm</surname><given-names>ER</given-names></name><name><surname>Tan</surname><given-names>JC</given-names></name><name><surname>Toris</surname><given-names>CB</given-names></name><name><surname>Torrejon</surname><given-names>KY</given-names></name><name><surname>Vranka</surname><given-names>JA</given-names></name><name><surname>Wirtz</surname><given-names>MK</given-names></name><name><surname>Yorio</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zode</surname><given-names>GS</given-names></name><name><surname>Fautsch</surname><given-names>MP</given-names></name><name><surname>Peters</surname><given-names>DM</given-names></name><name><surname>Acott</surname><given-names>TS</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Consensus recommendations for trabecular meshwork cell isolation, characterization and culture</article-title><source>Experimental Eye Research</source><volume>171</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2018.03.001</pub-id><pub-id pub-id-type="pmid">29526795</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>CJ</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Fecto</surname><given-names>F</given-names></name><name><surname>Donaghy</surname><given-names>M</given-names></name><name><surname>Nicholson</surname><given-names>G</given-names></name><name><surname>McEntagart</surname><given-names>ME</given-names></name><name><surname>Crosby</surname><given-names>AH</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>H</given-names></name><name><surname>McEvoy</surname><given-names>KM</given-names></name><name><surname>Siddique</surname><given-names>T</given-names></name><name><surname>Deng</surname><given-names>H-X</given-names></name><name><surname>Dyck</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TRPV4 mutations and cytotoxic hypercalcemia in axonal Charcot-Marie-Tooth neuropathies</article-title><source>Neurology</source><volume>76</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31820f2de3</pub-id><pub-id pub-id-type="pmid">21288981</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Krizaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>No Cell Is an Island: Trabecular Meshwork Ion Channels as Sensors of the Ambient Milieu” in Glaucoma Research and Clinical Advances</source><publisher-name>Kugler Publications</publisher-name></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>GF</given-names></name><name><surname>Gorusupudi</surname><given-names>A</given-names></name><name><surname>Enyong</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Bernstein</surname><given-names>PS</given-names></name><name><surname>Toft-Bertelsen</surname><given-names>T</given-names></name><name><surname>MacAulay</surname><given-names>N</given-names></name><name><surname>Elliott</surname><given-names>MH</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension</article-title><source>Journal of Lipid Research</source><volume>62</volume><elocation-id>100145</elocation-id><pub-id pub-id-type="doi">10.1016/j.jlr.2021.100145</pub-id><pub-id pub-id-type="pmid">34710431</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TRPV4-Rho signaling drives cytoskeletal and focal adhesion remodeling in trabecular meshwork cells</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>320</volume><fpage>C1013</fpage><lpage>C1030</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00599.2020</pub-id><pub-id pub-id-type="pmid">33788628</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapajne</surname><given-names>L</given-names></name><name><surname>Rudzitis</surname><given-names>CN</given-names></name><name><surname>Cullimore</surname><given-names>B</given-names></name><name><surname>Ryskamp</surname><given-names>D</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Redmon</surname><given-names>SN</given-names></name><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Krizaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>TRPV4: Cell type-specific activation, regulation and function in the vertebrate eye</article-title><source>Current Topics in Membranes</source><volume>89</volume><fpage>189</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/bs.ctm.2022.07.005</pub-id><pub-id pub-id-type="pmid">36210149</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Last</surname><given-names>JA</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Reilly</surname><given-names>CM</given-names></name><name><surname>Keller</surname><given-names>K</given-names></name><name><surname>Acott</surname><given-names>TS</given-names></name><name><surname>Fautsch</surname><given-names>MP</given-names></name><name><surname>Murphy</surname><given-names>CJ</given-names></name><name><surname>Russell</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Elastic modulus determination of normal and glaucomatous human trabecular meshwork</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>52</volume><fpage>2147</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-6342</pub-id><pub-id pub-id-type="pmid">21220561</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leske</surname><given-names>MC</given-names></name><name><surname>Heijl</surname><given-names>A</given-names></name><name><surname>Hussein</surname><given-names>M</given-names></name><name><surname>Bengtsson</surname><given-names>B</given-names></name><name><surname>Hyman</surname><given-names>L</given-names></name><name><surname>Komaroff</surname><given-names>E</given-names></name><collab>Early Manifest Glaucoma Trial Group</collab></person-group><year iso-8601-date="2003">2003</year><article-title>Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial</article-title><source>Archives of Ophthalmology</source><volume>121</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1001/archopht.121.1.48</pub-id><pub-id pub-id-type="pmid">12523884</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Henty-Ridilla</surname><given-names>JL</given-names></name><name><surname>Bernstein</surname><given-names>AM</given-names></name><name><surname>Ganapathy</surname><given-names>PS</given-names></name><name><surname>Herberg</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>TGFβ2 regulates human trabecular meshwork cell contractility <italic>via</italic> ERK and ROCK pathways with distinct signaling crosstalk dependent on the culture substrate</article-title><source>Current Eye Research</source><volume>47</volume><fpage>1165</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1080/02713683.2022.2071943</pub-id><pub-id pub-id-type="pmid">35481448</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Raghunathan</surname><given-names>VK</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name><name><surname>Ganapathy</surname><given-names>PS</given-names></name><name><surname>Herberg</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Extracellular matrix stiffness and TGFβ2 regulate YAP/TAZ activity in human trabecular meshwork cells</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>e4342</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.844342</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Abnormal osmotic regulation in trpv4-/- mice</article-title><source>PNAS</source><volume>100</volume><fpage>13698</fpage><lpage>13703</lpage><pub-id pub-id-type="doi">10.1073/pnas.1735416100</pub-id><pub-id pub-id-type="pmid">14581612</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>N</given-names></name><name><surname>Conwell</surname><given-names>MD</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Kettenhofen</surname><given-names>CI</given-names></name><name><surname>Westlake</surname><given-names>CJ</given-names></name><name><surname>Cantor</surname><given-names>LB</given-names></name><name><surname>Wells</surname><given-names>CD</given-names></name><name><surname>Weinreb</surname><given-names>RN</given-names></name><name><surname>Corson</surname><given-names>TW</given-names></name><name><surname>Spandau</surname><given-names>DF</given-names></name><name><surname>Joos</surname><given-names>KM</given-names></name><name><surname>Iomini</surname><given-names>C</given-names></name><name><surname>Obukhov</surname><given-names>AG</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Primary cilia signaling mediates intraocular pressure sensation</article-title><source>PNAS</source><volume>111</volume><fpage>12871</fpage><lpage>12876</lpage><pub-id pub-id-type="doi">10.1073/pnas.1323292111</pub-id><pub-id pub-id-type="pmid">25143588</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maqboul</surname><given-names>A</given-names></name><name><surname>Elsadek</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expression profiles of TRPV1, TRPV4, TLR4 and ERK1/2 in the dorsal root ganglionic neurons of a cancer-induced neuropathy rat model</article-title><source>PeerJ</source><volume>6</volume><elocation-id>e4622</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.4622</pub-id><pub-id pub-id-type="pmid">29637027</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>Y</given-names></name><name><surname>Hirakawa</surname><given-names>H</given-names></name><name><surname>Shigeto</surname><given-names>T</given-names></name><name><surname>Futagami</surname><given-names>M</given-names></name><name><surname>Mizunuma</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action</article-title><source>Molecular Pain</source><volume>10</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.1186/1744-8069-10-61</pub-id><pub-id pub-id-type="pmid">25240613</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>BD</given-names></name><name><surname>Thodeti</surname><given-names>CK</given-names></name><name><surname>Tytell</surname><given-names>JD</given-names></name><name><surname>Mammoto</surname><given-names>A</given-names></name><name><surname>Overby</surname><given-names>DR</given-names></name><name><surname>Ingber</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ultra-rapid activation of TRPV4 ion channels by mechanical forces applied to cell surface beta1 integrins</article-title><source>Integrative Biology</source><volume>2</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1039/c0ib00034e</pub-id><pub-id pub-id-type="pmid">20725677</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina-Ortiz</surname><given-names>WE</given-names></name><name><surname>Belmares</surname><given-names>R</given-names></name><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Wordinger</surname><given-names>RJ</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cellular fibronectin expression in human trabecular meshwork and induction by transforming growth factor-β2</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>54</volume><fpage>6779</fpage><lpage>6788</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-12298</pub-id><pub-id pub-id-type="pmid">24030464</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montecchi-Palmer</surname><given-names>M</given-names></name><name><surname>Bermudez</surname><given-names>JY</given-names></name><name><surname>Webber</surname><given-names>HC</given-names></name><name><surname>Patel</surname><given-names>GC</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name><name><surname>Mao</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TGFβ2 induces the formation of Cross-Linked Actin Networks (CLANs) in human trabecular meshwork cells through the smad and non-smad dependent pathways</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>58</volume><elocation-id>1288</elocation-id><pub-id pub-id-type="doi">10.1167/iovs.16-19672</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nettesheim</surname><given-names>A</given-names></name><name><surname>Shim</surname><given-names>MS</given-names></name><name><surname>Hirt</surname><given-names>J</given-names></name><name><surname>Liton</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptome analysis reveals autophagy as regulator of TGFβ/Smad-induced fibrogenesis in trabecular meshwork cells</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>16092</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-52627-2</pub-id><pub-id pub-id-type="pmid">31695131</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilius</surname><given-names>B</given-names></name><name><surname>Voets</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The puzzle of TRPV4 channelopathies</article-title><source>EMBO Reports</source><volume>14</volume><fpage>152</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1038/embor.2012.219</pub-id><pub-id pub-id-type="pmid">23306656</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimoto</surname><given-names>R</given-names></name><name><surname>Derouiche</surname><given-names>S</given-names></name><name><surname>Eto</surname><given-names>K</given-names></name><name><surname>Deveci</surname><given-names>A</given-names></name><name><surname>Kashio</surname><given-names>M</given-names></name><name><surname>Kimori</surname><given-names>Y</given-names></name><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Morimatsu</surname><given-names>H</given-names></name><name><surname>Nabekura</surname><given-names>J</given-names></name><name><surname>Tominaga</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Thermosensitive TRPV4 channels mediate temperature-dependent microglia movement</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2012894118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2012894118</pub-id><pub-id pub-id-type="pmid">33888579</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochiai</surname><given-names>Y</given-names></name><name><surname>Ochiai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes</article-title><source>Japanese Journal of Ophthalmology</source><volume>46</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/s0021-5155(01)00523-8</pub-id><pub-id pub-id-type="pmid">12063033</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Conor</surname><given-names>CJ</given-names></name><name><surname>Leddy</surname><given-names>HA</given-names></name><name><surname>Benefield</surname><given-names>HC</given-names></name><name><surname>Liedtke</surname><given-names>WB</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading</article-title><source>PNAS</source><volume>111</volume><fpage>1316</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1073/pnas.1319569111</pub-id><pub-id pub-id-type="pmid">24474754</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overby</surname><given-names>DR</given-names></name><name><surname>Bertrand</surname><given-names>J</given-names></name><name><surname>Schicht</surname><given-names>M</given-names></name><name><surname>Paulsen</surname><given-names>F</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name><name><surname>Lütjen-Drecoll</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>55</volume><fpage>3727</fpage><lpage>3736</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-13699</pub-id><pub-id pub-id-type="pmid">24833737</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>G</given-names></name><name><surname>Fury</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Gomez-Caraballo</surname><given-names>M</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Adler</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>M</given-names></name><name><surname>Schmitt</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Yancopoulos</surname><given-names>G</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name><name><surname>Romano</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular taxonomy of human ocular outflow tissues defined by single-cell transcriptomics</article-title><source>PNAS</source><volume>117</volume><fpage>12856</fpage><lpage>12867</lpage><pub-id pub-id-type="doi">10.1073/pnas.2001896117</pub-id><pub-id pub-id-type="pmid">32439707</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>PD</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Kasetti</surname><given-names>RB</given-names></name><name><surname>Maddineni</surname><given-names>P</given-names></name><name><surname>Mayhew</surname><given-names>W</given-names></name><name><surname>Millar</surname><given-names>JC</given-names></name><name><surname>Ellis</surname><given-names>DZ</given-names></name><name><surname>Sonkusare</surname><given-names>SK</given-names></name><name><surname>Zode</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impaired TRPV4-eNOS signaling in trabecular meshwork elevates intraocular pressure in glaucoma</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2022461118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2022461118</pub-id><pub-id pub-id-type="pmid">33853948</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>SV</given-names></name><name><surname>Kasetti</surname><given-names>RB</given-names></name><name><surname>Millar</surname><given-names>JC</given-names></name><name><surname>Zode</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A novel mouse model of TGFβ2-induced ocular hypertension using lentiviral gene delivery</article-title><source>International Journal of Molecular Sciences</source><volume>23</volume><elocation-id>6883</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23136883</pub-id><pub-id pub-id-type="pmid">35805889</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattabiraman</surname><given-names>PP</given-names></name><name><surname>Rinkoski</surname><given-names>T</given-names></name><name><surname>Poeschla</surname><given-names>E</given-names></name><name><surname>Proia</surname><given-names>A</given-names></name><name><surname>Challa</surname><given-names>P</given-names></name><name><surname>Rao</surname><given-names>PV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork</article-title><source>The American Journal of Pathology</source><volume>185</volume><fpage>496</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2014.10.023</pub-id><pub-id pub-id-type="pmid">25499974</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phuong</surname><given-names>TTT</given-names></name><name><surname>Redmon</surname><given-names>SN</given-names></name><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Winter</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>DY</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Calcium influx through TRPV4 channels modulates the adherens contacts between retinal microvascular endothelial cells</article-title><source>The Journal of Physiology</source><volume>595</volume><fpage>6869</fpage><lpage>6885</lpage><pub-id pub-id-type="doi">10.1113/JP275052</pub-id><pub-id pub-id-type="pmid">28949006</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pochynyuk</surname><given-names>O</given-names></name><name><surname>Zaika</surname><given-names>O</given-names></name><name><surname>O’Neil</surname><given-names>RG</given-names></name><name><surname>Mamenko</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Novel insights into TRPV4 function in the kidney</article-title><source>Pflugers Archiv</source><volume>465</volume><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1007/s00424-012-1190-z</pub-id><pub-id pub-id-type="pmid">23207579</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahaman</surname><given-names>SO</given-names></name><name><surname>Grove</surname><given-names>LM</given-names></name><name><surname>Paruchuri</surname><given-names>S</given-names></name><name><surname>Southern</surname><given-names>BD</given-names></name><name><surname>Abraham</surname><given-names>S</given-names></name><name><surname>Niese</surname><given-names>KA</given-names></name><name><surname>Scheraga</surname><given-names>RG</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Thodeti</surname><given-names>CK</given-names></name><name><surname>Zhang</surname><given-names>DX</given-names></name><name><surname>Moran</surname><given-names>MM</given-names></name><name><surname>Schilling</surname><given-names>WP</given-names></name><name><surname>Tschumperlin</surname><given-names>DJ</given-names></name><name><surname>Olman</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>5225</fpage><lpage>5238</lpage><pub-id pub-id-type="doi">10.1172/JCI75331</pub-id><pub-id pub-id-type="pmid">25365224</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>PV</given-names></name><name><surname>Pattabiraman</surname><given-names>PP</given-names></name><name><surname>Kopczynski</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research</article-title><source>Experimental Eye Research</source><volume>158</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2016.08.023</pub-id><pub-id pub-id-type="pmid">27593914</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raychaudhuri</surname><given-names>U</given-names></name><name><surname>Millar</surname><given-names>JC</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tissue transglutaminase elevates intraocular pressure in mice</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>58</volume><elocation-id>6197</elocation-id><pub-id pub-id-type="doi">10.1167/iovs.17-22236</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>AT</given-names></name><name><surname>Chan</surname><given-names>DWH</given-names></name><name><surname>Ethier</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Actin structure in the outflow tract of normal and glaucomatous eyes</article-title><source>Experimental Eye Research</source><volume>84</volume><fpage>214</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2005.10.035</pub-id><pub-id pub-id-type="pmid">17219625</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Redmon</surname><given-names>SN</given-names></name><name><surname>Shibasaki</surname><given-names>K</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><chapter-title>Transient receptor potential cation channel subfamily v member 4 (TRPV4)</chapter-title><person-group person-group-type="editor"><name><surname>Choi</surname><given-names>S</given-names></name></person-group><source>Encyclopedia of Signaling Molecules</source><publisher-name>Springer</publisher-name><fpage>5665</fpage><lpage>5675</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-67199-4_101977</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Redmon</surname><given-names>SN</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Tseng</surname><given-names>YT</given-names></name><name><surname>Rudzitis</surname><given-names>CN</given-names></name><name><surname>Searle</surname><given-names>JE</given-names></name><name><surname>Ahmed</surname><given-names>F</given-names></name><name><surname>Unser</surname><given-names>A</given-names></name><name><surname>Borrás</surname><given-names>T</given-names></name><name><surname>Torrejon</surname><given-names>K</given-names></name><name><surname>Krizaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>TRPV4 subserves physiological and pathological elevations in intraocular pressure</article-title><source>Research Sqaure</source><pub-id pub-id-type="doi">10.21203/rs.3.rs-4714050/v1</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reina-Torres</surname><given-names>E</given-names></name><name><surname>De Ieso</surname><given-names>ML</given-names></name><name><surname>Pasquale</surname><given-names>LR</given-names></name><name><surname>Madekurozwa</surname><given-names>M</given-names></name><name><surname>van Batenburg-Sherwood</surname><given-names>J</given-names></name><name><surname>Overby</surname><given-names>DR</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The vital role for nitric oxide in intraocular pressure homeostasis</article-title><source>Progress in Retinal and Eye Research</source><volume>83</volume><elocation-id>100922</elocation-id><pub-id pub-id-type="doi">10.1016/j.preteyeres.2020.100922</pub-id><pub-id pub-id-type="pmid">33253900</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>MWG</given-names></name><name><surname>Sui</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Rong</surname><given-names>W</given-names></name><name><surname>Wildman</surname><given-names>S</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Langley</surname><given-names>S</given-names></name><name><surname>Ruggieri</surname><given-names>MR</given-names><suffix>Sr</suffix></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TRPV4 receptor as a functional sensory molecule in bladder urothelium: stretch-independent, tissue-specific actions and pathological implications</article-title><source>FASEB Journal</source><volume>34</volume><fpage>263</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1096/fj.201900961RR</pub-id><pub-id pub-id-type="pmid">31914645</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryskamp</surname><given-names>DA</given-names></name><name><surname>Witkovsky</surname><given-names>P</given-names></name><name><surname>Barabas</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Koehler</surname><given-names>C</given-names></name><name><surname>Akimov</surname><given-names>NP</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Chauhan</surname><given-names>S</given-names></name><name><surname>Xing</surname><given-names>W</given-names></name><name><surname>Rentería</surname><given-names>RC</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Krizaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The polymodal ion channel transient receptor potential vanilloid 4 modulates calcium flux, spiking rate, and apoptosis of mouse retinal ganglion cells</article-title><source>The Journal of Neuroscience</source><volume>31</volume><fpage>7089</fpage><lpage>7101</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0359-11.2011</pub-id><pub-id pub-id-type="pmid">21562271</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryskamp</surname><given-names>DA</given-names></name><name><surname>Frye</surname><given-names>AM</given-names></name><name><surname>Phuong</surname><given-names>TTT</given-names></name><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Jo</surname><given-names>AO</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Iuso</surname><given-names>A</given-names></name><name><surname>Redmon</surname><given-names>SN</given-names></name><name><surname>Ambati</surname><given-names>B</given-names></name><name><surname>Hageman</surname><given-names>G</given-names></name><name><surname>Prestwich</surname><given-names>GD</given-names></name><name><surname>Torrejon</surname><given-names>KY</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TRPV4 regulates calcium homeostasis, cytoskeletal remodeling, conventional outflow and intraocular pressure in the mammalian eye</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>30583</elocation-id><pub-id pub-id-type="doi">10.1038/srep30583</pub-id><pub-id pub-id-type="pmid">27510430</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>BC</given-names></name><name><surname>Hammes</surname><given-names>NM</given-names></name><name><surname>Johnson</surname><given-names>PL</given-names></name><name><surname>Shekhar</surname><given-names>A</given-names></name><name><surname>McKinnon</surname><given-names>SJ</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dorsomedial/Perifornical hypothalamic stimulation increases intraocular pressure, intracranial pressure, and the translaminar pressure gradient</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>53</volume><fpage>7328</fpage><lpage>7335</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-10632</pub-id><pub-id pub-id-type="pmid">23033392</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>B</given-names></name><name><surname>Gutierrez-Cañas</surname><given-names>I</given-names></name><name><surname>Dotor</surname><given-names>J</given-names></name><name><surname>Palao</surname><given-names>G</given-names></name><name><surname>Lasarte</surname><given-names>JJ</given-names></name><name><surname>Ruiz</surname><given-names>J</given-names></name><name><surname>Prieto</surname><given-names>J</given-names></name><name><surname>Borrás-Cuesta</surname><given-names>F</given-names></name><name><surname>Pablos</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis</article-title><source>The Journal of Investigative Dermatology</source><volume>125</volume><fpage>450</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23859.x</pub-id><pub-id pub-id-type="pmid">16117784</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness</article-title><source>Experimental Eye Research</source><volume>232</volume><elocation-id>109444</elocation-id><pub-id pub-id-type="doi">10.1016/j.exer.2023.109444</pub-id><pub-id pub-id-type="pmid">36958427</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Goswami</surname><given-names>R</given-names></name><name><surname>Merth</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>KY</given-names></name><name><surname>Zhang</surname><given-names>DX</given-names></name><name><surname>Rahaman</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TRPV4 ion channel is a novel regulator of dermal myofibroblast differentiation</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>312</volume><fpage>C562</fpage><lpage>C572</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00187.2016</pub-id><pub-id pub-id-type="pmid">28249987</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>KZ</given-names></name><name><surname>North</surname><given-names>RA</given-names></name><name><surname>Surprenant</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Potassium channels opened by noradrenaline and other transmitters in excised membrane patches of guinea-pig submucosal neurones</article-title><source>The Journal of Physiology</source><volume>445</volume><fpage>581</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1992.sp018941</pub-id><pub-id pub-id-type="pmid">1354259</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepard</surname><given-names>AR</given-names></name><name><surname>Millar</surname><given-names>JC</given-names></name><name><surname>Pang</surname><given-names>IH</given-names></name><name><surname>Jacobson</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>WH</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Adenoviral gene transfer of active human transforming growth factor-β2 elevates intraocular pressure and reduces outflow facility in rodent eyes</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>51</volume><elocation-id>2067</elocation-id><pub-id pub-id-type="doi">10.1167/iovs.09-4567</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>AK</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Shenoy</surname><given-names>SK</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Arresting a transient receptor potential (TRP) channel: beta-arrestin 1 mediates ubiquitination and functional down-regulation of TRPV4</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>30115</fpage><lpage>30125</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.141549</pub-id><pub-id pub-id-type="pmid">20650893</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TRPV4 Channel Inhibits TGF-β1-induced proliferation of hepatic stellate cells</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e101179</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0101179</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamer</surname><given-names>WD</given-names></name><name><surname>Seftor</surname><given-names>REB</given-names></name><name><surname>Williams</surname><given-names>SK</given-names></name><name><surname>Samaha</surname><given-names>HAM</given-names></name><name><surname>Snyder</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion</article-title><source>Current Eye Research</source><volume>14</volume><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.3109/02713689508998409</pub-id><pub-id pub-id-type="pmid">7587308</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>EA</given-names></name><name><surname>Wafford</surname><given-names>KA</given-names></name><name><surname>Brickley</surname><given-names>SG</given-names></name><name><surname>Franks</surname><given-names>NP</given-names></name><name><surname>Wisden</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The role of K₂p channels in anaesthesia and sleep</article-title><source>Pflugers Archiv</source><volume>467</volume><fpage>907</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1007/s00424-014-1654-4</pub-id><pub-id pub-id-type="pmid">25482669</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tham</surname><given-names>Y-C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Quigley</surname><given-names>HA</given-names></name><name><surname>Aung</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>C-Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis</article-title><source>Ophthalmology</source><volume>121</volume><fpage>2081</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2014.05.013</pub-id><pub-id pub-id-type="pmid">24974815</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thibodeau</surname><given-names>ML</given-names></name><name><surname>Peters</surname><given-names>CH</given-names></name><name><surname>Townsend</surname><given-names>KN</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Hendson</surname><given-names>G</given-names></name><name><surname>Adam</surname><given-names>S</given-names></name><name><surname>Selby</surname><given-names>K</given-names></name><name><surname>Macleod</surname><given-names>PM</given-names></name><name><surname>Gershome</surname><given-names>C</given-names></name><name><surname>Ruben</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><collab>FORGE Canada Consortium</collab><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Gibson</surname><given-names>WT</given-names></name><name><surname>Horvath</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Compound heterozygous TRPV4 mutations in two siblings with a complex phenotype including severe intellectual disability and neuropathy</article-title><source>American Journal of Medical Genetics. Part A</source><volume>173</volume><fpage>3087</fpage><lpage>3092</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.38400</pub-id><pub-id pub-id-type="pmid">28898540</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toft-Bertelsen</surname><given-names>TL</given-names></name><name><surname>Barbuskaite</surname><given-names>D</given-names></name><name><surname>Heerfordt</surname><given-names>EK</given-names></name><name><surname>Lolansen</surname><given-names>SD</given-names></name><name><surname>Andreassen</surname><given-names>SN</given-names></name><name><surname>Rostgaard</surname><given-names>N</given-names></name><name><surname>Olsen</surname><given-names>MH</given-names></name><name><surname>Norager</surname><given-names>NH</given-names></name><name><surname>Capion</surname><given-names>T</given-names></name><name><surname>Rath</surname><given-names>MF</given-names></name><name><surname>Juhler</surname><given-names>M</given-names></name><name><surname>MacAulay</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Lysophosphatidic acid as a CSF lipid in posthemorrhagic hydrocephalus that drives CSF accumulation via TRPV4-induced hyperactivation of NKCC1</article-title><source>Fluids and Barriers of the CNS</source><volume>19</volume><elocation-id>69</elocation-id><pub-id pub-id-type="doi">10.1186/s12987-022-00361-9</pub-id><pub-id pub-id-type="pmid">36068581</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>RC</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>WF</given-names></name><name><surname>Tripathi</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2</article-title><source>Experimental Eye Research</source><volume>59</volume><fpage>723</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1006/exer.1994.1158</pub-id><pub-id pub-id-type="pmid">7698265</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Yamagishi</surname><given-names>R</given-names></name><name><surname>Tokuoka</surname><given-names>SM</given-names></name><name><surname>Kita</surname><given-names>Y</given-names></name><name><surname>Sakata</surname><given-names>R</given-names></name><name><surname>Honjo</surname><given-names>M</given-names></name><name><surname>Aihara</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TRPV4 is activated by mechanical stimulation to induce prostaglandins release in trabecular meshwork, lowering intraocular pressure</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0258911</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0258911</pub-id><pub-id pub-id-type="pmid">34673834</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zyl</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>McAdams</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>YR</given-names></name><name><surname>Shekhar</surname><given-names>K</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Juric</surname><given-names>D</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis</article-title><source>PNAS</source><volume>117</volume><fpage>10339</fpage><lpage>10349</lpage><pub-id pub-id-type="doi">10.1073/pnas.2001250117</pub-id><pub-id pub-id-type="pmid">32341164</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Godin</surname><given-names>M</given-names></name><name><surname>Pelling</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanical stretch sustains myofibroblast phenotype and function in microtissues through latent TGF-β1 activation</article-title><source>Integrative Biology</source><volume>12</volume><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1093/intbio/zyaa015</pub-id><pub-id pub-id-type="pmid">32877929</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Read</surname><given-names>AT</given-names></name><name><surname>Sulchek</surname><given-names>T</given-names></name><name><surname>Ethier</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trabecular meshwork stiffness in glaucoma</article-title><source>Experimental Eye Research</source><volume>158</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2016.07.011</pub-id><pub-id pub-id-type="pmid">27448987</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>SC</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Forcing through tumor metastasis: the interplay between tissue rigidity and epithelial-mesenchymal transition</article-title><source>Trends in Cell Biology</source><volume>26</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.09.009</pub-id><pub-id pub-id-type="pmid">26508691</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreb</surname><given-names>RN</given-names></name><name><surname>Toris</surname><given-names>CB</given-names></name><name><surname>Gabelt</surname><given-names>BT</given-names></name><name><surname>Lindsey</surname><given-names>JD</given-names></name><name><surname>Kaufman</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Effects of prostaglandins on the aqueous humor outflow pathways</article-title><source>Survey of Ophthalmology</source><volume>47 Suppl 1</volume><fpage>S53</fpage><lpage>S64</lpage><pub-id pub-id-type="doi">10.1016/s0039-6257(02)00306-5</pub-id><pub-id pub-id-type="pmid">12204701</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Aortic smooth muscle TRPV4 channels regulate vasoconstriction in high salt-induced hypertension</article-title><source>Hypertension Research</source><volume>46</volume><fpage>2356</fpage><lpage>2367</lpage><pub-id pub-id-type="doi">10.1038/s41440-023-01363-2</pub-id><pub-id pub-id-type="pmid">37532951</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JPM</given-names></name><name><surname>Cibelli</surname><given-names>M</given-names></name><name><surname>Urban</surname><given-names>L</given-names></name><name><surname>Nilius</surname><given-names>B</given-names></name><name><surname>McGeown</surname><given-names>JG</given-names></name><name><surname>Nagy</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TRPV4: molecular conductor of a diverse orchestra</article-title><source>Physiological Reviews</source><volume>96</volume><fpage>911</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1152/physrev.00016.2015</pub-id><pub-id pub-id-type="pmid">27252279</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willard</surname><given-names>VP</given-names></name><name><surname>Leddy</surname><given-names>HA</given-names></name><name><surname>Palmer</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>C-L</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transient receptor potential vanilloid 4 as a regulator of induced pluripotent stem cell chondrogenesis</article-title><source>Stem Cells</source><volume>39</volume><fpage>1447</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1002/stem.3440</pub-id><pub-id pub-id-type="pmid">34427363</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wipff</surname><given-names>PJ</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name><name><surname>Meister</surname><given-names>JJ</given-names></name><name><surname>Hinz</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix</article-title><source>The Journal of Cell Biology</source><volume>179</volume><fpage>1311</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1083/jcb.200704042</pub-id><pub-id pub-id-type="pmid">18086923</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Rong</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Emerging roles of the TRPV4 channel in bladder physiology and dysfunction</article-title><source>The Journal of Physiology</source><volume>599</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1113/JP279776</pub-id><pub-id pub-id-type="pmid">33052604</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Feedback regulation of TGF-β signaling</article-title><source>Acta Biochimica et Biophysica Sinica</source><volume>50</volume><fpage>37</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmx129</pub-id><pub-id pub-id-type="pmid">29228156</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YF</given-names></name><name><surname>Sun</surname><given-names>YY</given-names></name><name><surname>Peters</surname><given-names>DM</given-names></name><name><surname>Keller</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The effects of mechanical stretch on integrins and filopodial-associated proteins in normal and glaucomatous trabecular meshwork cells</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>886706</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.886706</pub-id><pub-id pub-id-type="pmid">35573666</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Phuong</surname><given-names>TTT</given-names></name><name><surname>Bretz</surname><given-names>CA</given-names></name><name><surname>Olsen</surname><given-names>KW</given-names></name><name><surname>Baumann</surname><given-names>JM</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Crandall</surname><given-names>A</given-names></name><name><surname>Heurteaux</surname><given-names>C</given-names></name><name><surname>Hartnett</surname><given-names>ME</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>TREK-1 channels regulate pressure sensitivity and calcium signaling in trabecular meshwork cells</article-title><source>The Journal of General Physiology</source><volume>150</volume><fpage>1660</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1085/jgp.201812179</pub-id><pub-id pub-id-type="pmid">30446509</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Phuong</surname><given-names>TTT</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>TRPV4 does not regulate the distal retinal light response</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1074</volume><fpage>553</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-75402-4_67</pub-id><pub-id pub-id-type="pmid">29721987</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Phuong</surname><given-names>TTT</given-names></name><name><surname>Baumann</surname><given-names>JM</given-names></name><name><surname>De Ieso</surname><given-names>ML</given-names></name><name><surname>Vazquez-Chona</surname><given-names>F</given-names></name><name><surname>Rudzitis</surname><given-names>CN</given-names></name><name><surname>Sundberg</surname><given-names>C</given-names></name><name><surname>Lakk</surname><given-names>M</given-names></name><name><surname>Stamer</surname><given-names>WD</given-names></name><name><surname>Križaj</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Piezo1 channels mediate trabecular meshwork mechanotransduction and promote aqueous fluid outflow</article-title><source>The Journal of Physiology</source><volume>599</volume><fpage>571</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1113/JP281011</pub-id><pub-id pub-id-type="pmid">33226641</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>K</given-names></name><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy</article-title><source>Diabetes Research and Clinical Practice</source><volume>133</volume><fpage>124</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2017.08.018</pub-id><pub-id pub-id-type="pmid">28934669</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Maddala</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>PV</given-names></name></person-group><year iso-8601-date="2008">2008a</year><article-title>Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>295</volume><fpage>C1057</fpage><lpage>C1070</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00481.2007</pub-id><pub-id pub-id-type="pmid">18799648</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y-H</given-names></name><name><surname>Ge</surname><given-names>H-Y</given-names></name><name><surname>Arendt-Nielsen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Yue</surname><given-names>S-W</given-names></name></person-group><year iso-8601-date="2008">2008b</year><article-title>A transient receptor potential vanilloid 4 contributes to mechanical allodynia following chronic compression of dorsal root ganglion in rats</article-title><source>Neuroscience Letters</source><volume>432</volume><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2007.12.028</pub-id><pub-id pub-id-type="pmid">18206306</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Raman</surname><given-names>A</given-names></name><name><surname>Daniel</surname><given-names>E</given-names></name><name><surname>Metcalf</surname><given-names>J</given-names></name><name><surname>Reif</surname><given-names>G</given-names></name><name><surname>Pierucci-Alves</surname><given-names>F</given-names></name><name><surname>Wallace</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Overexpression of TGF-β1 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease</article-title><source>American Journal of Physiology-Renal Physiology</source><volume>319</volume><fpage>F1135</fpage><lpage>F1148</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00366.2020</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Ramsey</surname><given-names>KE</given-names></name><name><surname>Stephan</surname><given-names>DA</given-names></name><name><surname>Russell</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>45</volume><fpage>4023</fpage><lpage>4034</lpage><pub-id pub-id-type="doi">10.1167/iovs.04-0535</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhavoronkov</surname><given-names>A</given-names></name><name><surname>Izumchenko</surname><given-names>E</given-names></name><name><surname>Kanherkar</surname><given-names>RR</given-names></name><name><surname>Teka</surname><given-names>M</given-names></name><name><surname>Cantor</surname><given-names>C</given-names></name><name><surname>Manaye</surname><given-names>K</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name><name><surname>West</surname><given-names>MD</given-names></name><name><surname>Makarev</surname><given-names>E</given-names></name><name><surname>Csoka</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma</article-title><source>Cell Cycle</source><volume>15</volume><fpage>1643</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1080/15384101.2016.1170261</pub-id><pub-id pub-id-type="pmid">27229292</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>XE</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Dan</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Ha</surname><given-names>T</given-names></name><name><surname>An</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanical stress determines the configuration of TGFβ activation in articular cartilage</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1706</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21948-0</pub-id><pub-id pub-id-type="pmid">33731712</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>F</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Bahrani Fard</surname><given-names>MR</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Sui</surname><given-names>S</given-names></name><name><surname>Read</surname><given-names>AT</given-names></name><name><surname>Sherwood</surname><given-names>JM</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Overby</surname><given-names>DR</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Ethier</surname><given-names>CR</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The role of Piezo1 in conventional aqueous humor outflow dynamics</article-title><source>iScience</source><volume>24</volume><elocation-id>102042</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102042</pub-id><pub-id pub-id-type="pmid">33532718</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Vascular smooth muscle TRPV4 (Transient Receptor Potential Vanilloid Family Member 4) channels regulate vasoconstriction and blood pressure in obesity</article-title><source>Hypertension</source><volume>80</volume><fpage>757</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.122.20109</pub-id><pub-id pub-id-type="pmid">36794584</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104894.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Poole</surname><given-names>Kate</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>UNSW Sydney</institution><country>Australia</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This <bold>fundamental</bold> work extends our understanding of the role of TGFβ2 as a modulator of mechanosensing in the eye and identifies the TRPV4 ion channel as a common regulator of Trabecular Meshwork (TM) contractility and pathological OHT and the data and evidence provided are <bold>convincing</bold>. This work will clearly be of interest to researchers investigating the role of mechanosensors in the TM and may underpin future research into treatments that aim to lower intra ocular pressure. This work will additionally be of interest to the growing field of researchers investigating the regulation of force sensing via ion channels and their roles in health and disease, in particular the ion channel TRPV4.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104894.3.sa1</article-id><title-group><article-title>Reviewer #1 (public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This comprehensive study employed molecular, optical, electrophysiological and tonometric strategies to establish the role of TGFβ2 in transcription and functional expression of mechanosensitive channel isoforms alongside studies of TM contractility in biomimetic hydrogels, and intraocular pressure regulation in a mouse model of TGFβ2 -induced ocular hypertension. TGFβ2 upregulated expression of TRPV4 and PIEZO1 transcripts and time-dependently augmented functional TRPV4 activation. TRPV4 activation induced TM contractility whereas pharmacological inhibition suppressed TGFβ2-induced hypercontractility and abrogated ocular hypertension in eyes overexpressing TGFβ2. Trpv4-/- mice resisted TGFβ2-driven increases in IOP. These data establish a fundamental role of TGFβ as a modulator of mechanosensing and identifies TRPV4 channel as a common mechanism for TM contractility and pathological ocular hypertension.</p><p>The manuscript is very well written and details the important function of TRPV4 in TM cell function. These data provide novel therapeutic targets and potential for disease-altering therapeutics.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104894.3.sa2</article-id><title-group><article-title>Reviewer #2 (public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The manuscript by Christopher N. Rudzitis et al. describes the role of TGFβ2 in the transcription and functional expression of mechanosensitive channel isoforms, alongside studies on TM contractility in biomimetic hydrogels and intraocular pressure. Overall, it is a very interesting study, nicely designed, and will contribute to the available literature on TRPV4 sensitivity to mechanical forces.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104894.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rudzitis</surname><given-names>Christopher Nass</given-names></name><role specific-use="author">Author</role><aff><institution>University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lakk</surname><given-names>Monika</given-names></name><role specific-use="author">Author</role><aff><institution>University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Ayushi</given-names></name><role specific-use="author">Author</role><aff><institution>SUNY Upstate Medical University</institution><addr-line><named-content content-type="city">Syracuse</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Redmon</surname><given-names>Sarah N</given-names></name><role specific-use="author">Author</role><aff><institution>University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kirdajová</surname><given-names>Denisa</given-names></name><role specific-use="author">Author</role><aff><institution>University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tseng</surname><given-names>Yun-Ting</given-names></name><role specific-use="author">Author</role><aff><institution>University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>deIeso</surname><given-names>Michael L</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Stamer</surname><given-names>Dan</given-names></name><role specific-use="author">Author</role><aff><institution>Duke</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Herberg</surname><given-names>Samuel</given-names></name><role specific-use="author">Author</role><aff><institution>SUNY Upstate Medical University</institution><addr-line><named-content content-type="city">Syracuse</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Krizaj</surname><given-names>David</given-names></name><role specific-use="author">Author</role><aff><institution>University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>The experimental rigor and design of the noctural IOP experiments was weak with low n values and differing methods of IOP measurement (conscious versus anesthetized). The same method of IOP measurement needs to be used for all measurements to make any conclusions on the circadian patterns of IOP in each condition.</p></disp-quote><p>One of the goals of our study was to confirm the results from the Patel et al (2021; PMID33853948) study, which in which nocturnal IOP measurements were conducted in anesthetized mice and diurnal IOP measurements in awake animals but we agree with both Reviewers that IOP should be measured under identical experimental conditions. Parenthetically, the number of animals per each treatment paradigm in the original version (N = 4) was sufficient to produce statistical significance for diurnal control vs diurnal TGFB, and diurnal control vs nocturnal control conditions.</p><p>To address the comment, we generated an additional cohort of TGFb2-expressing mice (N = 6) in which nocturnal and diurnal measurements were performed in awake animals. The results are shown in the revised Figure 6. Similar to the anesthetized cohort, the diurnal IOP in Lv-TGFB2 mice was statistically indistinguishable from the nocturnal value, indicating that TGFB2-induced OHT is not additive to physiological (circadian) OHT. The TRPV4-dependence of ocular hypertension induced by physiological and pathological methods suggests that the channel functions as a final common mechanism for ocular hypertension.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Figure 1A-C. Often there is a difference between the massage (message?, op. authors) and transcript data. I recommend the authors to confirm with qPCR data with another mode of protein measurements.</p></disp-quote><p>We are not sure we understand the Reviewer’s comment regarding the “difference between the message and transcript data” but note that the mRNA data shown in panels A &amp; B are confirmatory of previously published transcriptomic and proteomic screens (eg, Fleenor et al., IOVS 2006; Bollinger et al., IOVS 2011; Callaghan et al., Scientific Reports 2022; Li et al., Current Eye Research 2022 etc) and were included to show that the transcriptional response of canonical SMAD and pro-fibrotic genes unfolds as predicted from previous work. With regard to TRPV4 signaling, we expand transcriptomic data with protein analysis (Western blots) and functional analyses (measurements of TRPV4-mediated current and calcium imaging). Transcriptomic, protein expression, electrophysiological and imaging experiments revealed a remarkable consistency in TGFB2-dependence of gene (Fig. 1C) and protein expression (Fig. 1D), transmembrane current (Fig. 3C) and intracellular calcium (Fig. 2).</p><p>Parenthetically, we attempted to get a sense for the TGFB2-dependence of Piezo1 protein expression by conducting Western blots with multiple antibodies and experimental conditions. These efforts were unsuccessful, presumably due to the complexity (30-40 TM domains) and large molecular weight (280-300 kDa) of the protein. We note, however, that Piezo1 signaling cannot account for the observed OHT given that studies by us and others (Yarishkin et al., 2021, PMID: 33226641 and Zhu et al., 2021; PMID: 33532718) associated Piezo1 signaling with facility increases. The revised m/s reads: “The suppression of outflow facility by Piezo1 inhibitors applied under in vitro and in vivo conditions (39, 81) instead suggests that Piezo1 opposes the hypertensive functions of TRPV4.” The preprint by Redmon et al. (bioRxiv 2024, PMID 39041037) expands the TRPV4-dependence of OHT to microbead-induced, steroid-induced and nocturnal models of OHT to indicate that TRPV4 functions as a universal driver of elevated IOP. We reiterate this in the revised Discussion.</p><disp-quote content-type="editor-comment"><p>Does direct TRPV4 activation also induce the expression of these markers? Does inhibition of TRPV4, after TGF-β treatment, prevent the expression of these markers? Is TRPV4 acting downstream of this response?</p></disp-quote><p>A RNASeq study conducted by us (Rudzitis et al., under review) suggests that the agonist GSK101 has minimal effect on the fibrotic and canonical pathways shown in panels A and B. These data are beyond the scope of the present study. They will be published elsewhere, however, we include the data associated with genes depicted in panels A and B for the reviewer at the end of this Response.</p><p>We conducted an additional series of experiments to test whether TGFB2-induced upregulation of the TRPV4 and Piezo1 genes is itself TRPV4-dependent. As shown in the new SFig. 1, upregulation of the two genes is unaffected by TRPV4 inhibition.</p><disp-quote content-type="editor-comment"><p>Figure 1D. Beta tubulin is not a membrane marker. Having staining of b tubulin in membrane fraction shows contamination from the cytoplasm. Does the overall expression also increase?</p></disp-quote><p>b-tubulin associates with the plasma membrane by binding to integral membrane proteins in the plasma and organellar membranes through palmitoylation and attachment to linker proteins and as an integral component of exocytotic vesicles (Wolff, BBA 2009; Hogerheide et al., PNAS 2017). The protein is often used as a loading control for the TRPV4 protein (please see <ext-link ext-link-type="uri" xlink:href="https://www.cellsignal.com/products/primary-antibodies/trpv4-antibody/65893">https://www.cellsignal.com/products/primary-antibodies/trpv4-antibody/65893</ext-link>; Grove et al., Science Signaling 2019 and Moore et al., PNAS 2013). Parenthetically, our RNASeq studies did not find modulation of b-tubulin expression by TGFβ2 [CNR and DK, unpublished observations].</p><p>We examined the overall (cytosolic and membrane) TRPV4 expression and observed, similarly to the membrane fraction alone (Figure 2), upregulation following cytokine stimulation:</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>Western blot, total protection extract from control and TGFb2-treated TM cells [Alomone antibody].</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104894-sa3-fig1-v1.tif"/></fig><p>These results in our estimation do not add to the overall narrative and were not included into the paper.</p><disp-quote content-type="editor-comment"><p>Figure 4A: it is not very clear. I recommend including a zoom image or better resolution image.</p></disp-quote><p>We include a whole-page image as the new SFigure 4.</p><disp-quote content-type="editor-comment"><p>Figure 5B and 6B. Why there is a difference between groups in pre-injection panel. As Figure 5A, in pre-injection, there is no difference between LV-TGFβ and LV-control while in 5B there is a significant difference between these groups.</p></disp-quote><p>We revised Figure Legends to clarify that “pre-injection” in Figures 5B and 6B refers to IOP measurements before the intracameral injection of HC-06 not pre-injection of lentiviral constructs.</p><disp-quote content-type="editor-comment"><p>Discussion section. Line 279: &quot;TRPV4 channels in cells treated with TGFβ2 are likely to be constitutively active&quot; ... needs to be discussed further.</p></disp-quote><p>We rewrote the paragraph to clarify that TRPV4 is a thermosensitive channel that is expected to be constitutively active at the incubator temperature:</p><p>“The effectiveness of TRPV4 inhibition in suppressing TGFB2-induced contractility (Fig. 4) is consistent with constitutive activation of TRPV4 channels in incubator-cultured cells. TRPV4 is a thermosensitive channel (Q10 ~10). Mouse TRPV4 is activated by physiological temperatures (Chung et al., 2003; Shibasaki et al., 2007) with peak activation between ~34 - 37oC (Guler et al., 2003). The several-fold increase in functional expression of the channel in TGFB2-treated cells (Fig. 2) would be expected to promote tonic influx of Ca2+ and Ca2+-dependent cellular signaling. The abrogation of the contractile response in the presence of HC-06 indicates that TRPV4-mediated Ca2+ influx represents the principal source of calcium that drives the contractile response. Consistent with this, supplementation with the agonist GSK101 was sufficient to evoke TM contraction (Fig. 4B).”</p><disp-quote content-type="editor-comment"><p>Line 280: &quot;The residual contractility in HC-06-treated cells may reflect TGFβ2-mediated contributions from Piezo1.&quot; Piezo1 has a low threshold for mechanosensitivity. How do the authors discuss the observation that, in the presence of Piezo1, TRPV4 has a more prominent mechanosensory function? Is this tied to TGFβ signalling?</p></disp-quote><p>This is an interesting question. Our macroscopic and single channel recordings of Piezo1 activity in TM cells recapitulate the time course published in the original Coste et al. (2010) study, showing the channel inactivates within 10-100 msec (Yarishkin et al., 2021). Thus, it is likely that the channel is largely inactivated during chronic ocular hypertension. Indeed, it has been suggested that resting membrane tension alone may be sufficient to inactivate Piezo1 (Lewis and Grandl, 2015), with cells grown on stiff substrates (e.g., under our experimental conditions) experiencing almost complete Piezo1 inactivation. We propose that the primary function of Piezo channels may be to sense and transduce transient mechanical loading. The remarkable IOP-lowering effectiveness of TRPV4 antagonists and knockdown indicates that - in contrast to Piezo1 - TRPV4 activation is sustained.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>The complete strain name for the Trpv4-/- mice are missing.</p></disp-quote><p>Corrected.</p><disp-quote content-type="editor-comment"><p>The layout for Figure 6 is confusing as HC-06 was only used in panels B and C but the labels are above panel A.</p></disp-quote><p>Corrected.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>Only two mice were used for the noctural IOP experiments. Justification for retreating the same mice in opposite eyes and counting it as n=4 is not rigorous or justified.</p></disp-quote><p>The number of mice investigated in the original submission was four. In Week 1, two mice underwent PBS injections and 2 two mice were treated with HC-06. After the baseline was re-established in Week 2, the treatments were reversed.</p><p>We supplemented these numbers with an additional cohort of 6 mice, with identical results re: nocturnal vs diurnal IOP. These data are presented in the revised Figure 6.</p><disp-quote content-type="editor-comment"><p>Why are daytime IOPs measured in awake mice but noctural IOP's measured in isoflurane anesthetized mice? Anesthesia is well known to effect IOP and using two different methods could alter the results, especially when comparing between the groups. This could be why you did not see a noctural rise in the TGFB injected eyes. The same method needs to be used for all measurements to make any conclusions on the circadian patterns of IOP in each condition.</p></disp-quote><p>This is a good point, please see our response above.</p></body></sub-article></article>